Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review

Purpose Vincristine is widely used as anticancer therapy for a variety of hematological malignancies. The treatment is limited by progressive vincristine-induced neuropathy, possibly including both peripheral sensory and motor nerves, autonomic nervous functions, and the central nervous system. This...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer chemotherapy and pharmacology Ročník 84; číslo 3; s. 471 - 485
Hlavní autoři: Madsen, Marie Lindhard, Due, Hanne, Ejskjær, Niels, Jensen, Paw, Madsen, Jakob, Dybkær, Karen
Médium: Journal Article
Jazyk:angličtina
Vydáno: Berlin/Heidelberg Springer Berlin Heidelberg 01.09.2019
Springer Nature B.V
Témata:
Antineoplastic Agents, Phytogenic - adverse effects
Autonomic nervous system
Blood cancer
Cancer Research
Central nervous system
Drug-Related Side Effects and Adverse Reactions - etiology
Drug-Related Side Effects and Adverse Reactions - pathology
Fluconazole
Hematologic Neoplasms - drug therapy
Hematologic Neoplasms - pathology
Humans
Itraconazole
Medicine
Medicine & Public Health
Neurotoxicity
Neurotoxicity Syndromes - etiology
Neurotoxicity Syndromes - pathology
Oncology
Peripheral neuropathy
Pharmacodynamics
Pharmacokinetics
Pharmacology/Toxicology
Prognosis
Quality of life
Review
Review Article
Reviews
Vincristine
Vincristine - adverse effects
Voriconazole
Biomarkers
Vincristine-induced neuropathy
Neurotoxicity
Hematologic malignancies
Vincristine
ISSN:0344-5704, 1432-0843, 1432-0843
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Purpose Vincristine is widely used as anticancer therapy for a variety of hematological malignancies. The treatment is limited by progressive vincristine-induced neuropathy, possibly including both peripheral sensory and motor nerves, autonomic nervous functions, and the central nervous system. This dose-limiting side-effect can diminish quality of life and, furthermore, cause discontinuation of vincristine treatment. The present review elucidates the current knowledge regarding vincristine-induced neuropathy in hematologic malignancies, focusing on neuropathy assessment, clinical and molecular predictive markers, drug–drug interference, prevention, and treatment. Methods This review is conducted by a systematic search strategy for the identification of relevant literature in the PubMed and Embase databases. Results No clinical parameters displayed convincing potential as predictors of vincristine-induced neuropathy; however, preexisting neuropathy was consistently reported to be associated with an increased risk of neurotoxicity. In contrast, molecular markers, including polymorphisms in genes involved in the pharmacodynamics and pharmacokinetics of vincristine, displayed great potential as predictive markers of neuropathy incidence and severity. Furthermore, antifungal drugs, such as itraconazole and voriconazole, decrease the metabolism of vincristine and consequently lead to severe neuropathy when co-administered with vincristine, underscoring why fluconazole should be the antifungal drug of choice. Conclusion Reports from the 71 included studies clearly emphasize the lack of consistency in neuropathy assessment, grading systems, and reporting, making it difficult to interpret results between studies. Thus, truer clinical and molecular markers could emerge if the consistency of neuropathy detection and reporting increases by the use of conventional standardized neuropathy assessment tools and grading scales.
AbstractList PurposeVincristine is widely used as anticancer therapy for a variety of hematological malignancies. The treatment is limited by progressive vincristine-induced neuropathy, possibly including both peripheral sensory and motor nerves, autonomic nervous functions, and the central nervous system. This dose-limiting side-effect can diminish quality of life and, furthermore, cause discontinuation of vincristine treatment. The present review elucidates the current knowledge regarding vincristine-induced neuropathy in hematologic malignancies, focusing on neuropathy assessment, clinical and molecular predictive markers, drug–drug interference, prevention, and treatment.MethodsThis review is conducted by a systematic search strategy for the identification of relevant literature in the PubMed and Embase databases.ResultsNo clinical parameters displayed convincing potential as predictors of vincristine-induced neuropathy; however, preexisting neuropathy was consistently reported to be associated with an increased risk of neurotoxicity. In contrast, molecular markers, including polymorphisms in genes involved in the pharmacodynamics and pharmacokinetics of vincristine, displayed great potential as predictive markers of neuropathy incidence and severity. Furthermore, antifungal drugs, such as itraconazole and voriconazole, decrease the metabolism of vincristine and consequently lead to severe neuropathy when co-administered with vincristine, underscoring why fluconazole should be the antifungal drug of choice.ConclusionReports from the 71 included studies clearly emphasize the lack of consistency in neuropathy assessment, grading systems, and reporting, making it difficult to interpret results between studies. Thus, truer clinical and molecular markers could emerge if the consistency of neuropathy detection and reporting increases by the use of conventional standardized neuropathy assessment tools and grading scales.
Vincristine is widely used as anticancer therapy for a variety of hematological malignancies. The treatment is limited by progressive vincristine-induced neuropathy, possibly including both peripheral sensory and motor nerves, autonomic nervous functions, and the central nervous system. This dose-limiting side-effect can diminish quality of life and, furthermore, cause discontinuation of vincristine treatment. The present review elucidates the current knowledge regarding vincristine-induced neuropathy in hematologic malignancies, focusing on neuropathy assessment, clinical and molecular predictive markers, drug-drug interference, prevention, and treatment.PURPOSEVincristine is widely used as anticancer therapy for a variety of hematological malignancies. The treatment is limited by progressive vincristine-induced neuropathy, possibly including both peripheral sensory and motor nerves, autonomic nervous functions, and the central nervous system. This dose-limiting side-effect can diminish quality of life and, furthermore, cause discontinuation of vincristine treatment. The present review elucidates the current knowledge regarding vincristine-induced neuropathy in hematologic malignancies, focusing on neuropathy assessment, clinical and molecular predictive markers, drug-drug interference, prevention, and treatment.This review is conducted by a systematic search strategy for the identification of relevant literature in the PubMed and Embase databases.METHODSThis review is conducted by a systematic search strategy for the identification of relevant literature in the PubMed and Embase databases.No clinical parameters displayed convincing potential as predictors of vincristine-induced neuropathy; however, preexisting neuropathy was consistently reported to be associated with an increased risk of neurotoxicity. In contrast, molecular markers, including polymorphisms in genes involved in the pharmacodynamics and pharmacokinetics of vincristine, displayed great potential as predictive markers of neuropathy incidence and severity. Furthermore, antifungal drugs, such as itraconazole and voriconazole, decrease the metabolism of vincristine and consequently lead to severe neuropathy when co-administered with vincristine, underscoring why fluconazole should be the antifungal drug of choice.RESULTSNo clinical parameters displayed convincing potential as predictors of vincristine-induced neuropathy; however, preexisting neuropathy was consistently reported to be associated with an increased risk of neurotoxicity. In contrast, molecular markers, including polymorphisms in genes involved in the pharmacodynamics and pharmacokinetics of vincristine, displayed great potential as predictive markers of neuropathy incidence and severity. Furthermore, antifungal drugs, such as itraconazole and voriconazole, decrease the metabolism of vincristine and consequently lead to severe neuropathy when co-administered with vincristine, underscoring why fluconazole should be the antifungal drug of choice.Reports from the 71 included studies clearly emphasize the lack of consistency in neuropathy assessment, grading systems, and reporting, making it difficult to interpret results between studies. Thus, truer clinical and molecular markers could emerge if the consistency of neuropathy detection and reporting increases by the use of conventional standardized neuropathy assessment tools and grading scales.CONCLUSIONReports from the 71 included studies clearly emphasize the lack of consistency in neuropathy assessment, grading systems, and reporting, making it difficult to interpret results between studies. Thus, truer clinical and molecular markers could emerge if the consistency of neuropathy detection and reporting increases by the use of conventional standardized neuropathy assessment tools and grading scales.
Vincristine is widely used as anticancer therapy for a variety of hematological malignancies. The treatment is limited by progressive vincristine-induced neuropathy, possibly including both peripheral sensory and motor nerves, autonomic nervous functions, and the central nervous system. This dose-limiting side-effect can diminish quality of life and, furthermore, cause discontinuation of vincristine treatment. The present review elucidates the current knowledge regarding vincristine-induced neuropathy in hematologic malignancies, focusing on neuropathy assessment, clinical and molecular predictive markers, drug-drug interference, prevention, and treatment. This review is conducted by a systematic search strategy for the identification of relevant literature in the PubMed and Embase databases. No clinical parameters displayed convincing potential as predictors of vincristine-induced neuropathy; however, preexisting neuropathy was consistently reported to be associated with an increased risk of neurotoxicity. In contrast, molecular markers, including polymorphisms in genes involved in the pharmacodynamics and pharmacokinetics of vincristine, displayed great potential as predictive markers of neuropathy incidence and severity. Furthermore, antifungal drugs, such as itraconazole and voriconazole, decrease the metabolism of vincristine and consequently lead to severe neuropathy when co-administered with vincristine, underscoring why fluconazole should be the antifungal drug of choice. Reports from the 71 included studies clearly emphasize the lack of consistency in neuropathy assessment, grading systems, and reporting, making it difficult to interpret results between studies. Thus, truer clinical and molecular markers could emerge if the consistency of neuropathy detection and reporting increases by the use of conventional standardized neuropathy assessment tools and grading scales.
Purpose Vincristine is widely used as anticancer therapy for a variety of hematological malignancies. The treatment is limited by progressive vincristine-induced neuropathy, possibly including both peripheral sensory and motor nerves, autonomic nervous functions, and the central nervous system. This dose-limiting side-effect can diminish quality of life and, furthermore, cause discontinuation of vincristine treatment. The present review elucidates the current knowledge regarding vincristine-induced neuropathy in hematologic malignancies, focusing on neuropathy assessment, clinical and molecular predictive markers, drug–drug interference, prevention, and treatment. Methods This review is conducted by a systematic search strategy for the identification of relevant literature in the PubMed and Embase databases. Results No clinical parameters displayed convincing potential as predictors of vincristine-induced neuropathy; however, preexisting neuropathy was consistently reported to be associated with an increased risk of neurotoxicity. In contrast, molecular markers, including polymorphisms in genes involved in the pharmacodynamics and pharmacokinetics of vincristine, displayed great potential as predictive markers of neuropathy incidence and severity. Furthermore, antifungal drugs, such as itraconazole and voriconazole, decrease the metabolism of vincristine and consequently lead to severe neuropathy when co-administered with vincristine, underscoring why fluconazole should be the antifungal drug of choice. Conclusion Reports from the 71 included studies clearly emphasize the lack of consistency in neuropathy assessment, grading systems, and reporting, making it difficult to interpret results between studies. Thus, truer clinical and molecular markers could emerge if the consistency of neuropathy detection and reporting increases by the use of conventional standardized neuropathy assessment tools and grading scales.
Author Madsen, Marie Lindhard
Jensen, Paw
Ejskjær, Niels
Madsen, Jakob
Due, Hanne
Dybkær, Karen
Author_xml – sequence: 1
  givenname: Marie Lindhard
  surname: Madsen
  fullname: Madsen, Marie Lindhard
  organization: Department of Hematology, Aalborg University Hospital
– sequence: 2
  givenname: Hanne
  surname: Due
  fullname: Due, Hanne
  organization: Department of Hematology, Aalborg University Hospital, Department of Clinical Medicine, Aalborg University
– sequence: 3
  givenname: Niels
  surname: Ejskjær
  fullname: Ejskjær, Niels
  organization: Department of Clinical Medicine, Aalborg University, Steno Diabetes Center North Denmark, Aalborg University Hospital
– sequence: 4
  givenname: Paw
  surname: Jensen
  fullname: Jensen, Paw
  organization: Department of Hematology, Aalborg University Hospital, Clinical Cancer Research Center, Aalborg University Hospital
– sequence: 5
  givenname: Jakob
  surname: Madsen
  fullname: Madsen, Jakob
  organization: Department of Hematology, Aalborg University Hospital
– sequence: 6
  givenname: Karen
  surname: Dybkær
  fullname: Dybkær, Karen
  email: k.dybkaer@rn.dk
  organization: Department of Hematology, Aalborg University Hospital, Department of Clinical Medicine, Aalborg University, Clinical Cancer Research Center, Aalborg University Hospital
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31214762$$D View this record in MEDLINE/PubMed
BookMark eNp9kUtvFDEQhC0URDaBP8ABjcSFy0D7MS8OSFGUAFIkLsmFi-Wxe3YdzdiL7Vm0_z6ebMIjh5wsub8qVXedkCPnHRLylsJHCtB8igCshRJoVwJvW1FWL8iKCs5KaAU_IivgIn82II7JSYy3ACAo56_IMaeMiqZmK_LzLG5Rp1j4odhZp4ONyTosrTOzRlM4nIPfqrTZF9YVG5xU8qNfW11MarRrp5y2GD8Xqoj7mJZxHgXcWfz9mrwc1BjxzcN7Sm4uL67Pv5VXP75-Pz-7KnUlIJUaheENbyuTU_V0yAuAMhWt-5oKAXXFAXujWgVCDR0aBqZDJXRXYw-VYfyUfDn4bud-QqPRpaBGuQ12UmEvvbLy_4mzG7n2O1nXLasang0-PBgE_2vGmORko8ZxVA79HCVjgouOCrag75-gt34OLq-3UKwWOXyXqXf_JvoT5fHsGWgPgA4-xoCD1Dbl0_kloB0lBbk0LA8Ny9ywvG9YVlnKnkgf3Z8V8YMoZtitMfyN_YzqDhwZubA
CitedBy_id crossref_primary_10_1080_08880018_2022_2047849
crossref_primary_10_1080_10428194_2020_1742907
crossref_primary_10_1002_jat_4521
crossref_primary_10_1002_ibra_12086
crossref_primary_10_1016_j_neuint_2020_104841
crossref_primary_10_1182_bloodadvances_2024014695
crossref_primary_10_2174_1573412919666221123110420
crossref_primary_10_3390_cancers14030612
crossref_primary_10_3390_toxics9090218
crossref_primary_10_1007_s00210_022_02254_y
crossref_primary_10_3390_ijms251910389
crossref_primary_10_1177_18758894251347128
crossref_primary_10_1016_j_jchromb_2025_124592
crossref_primary_10_1212_CON_0000000000000943
crossref_primary_10_3389_fphar_2023_1213763
crossref_primary_10_1016_j_jddst_2022_103545
crossref_primary_10_1080_17568919_2025_2546774
crossref_primary_10_1016_j_phoj_2023_06_004
crossref_primary_10_1093_jac_dkac060
crossref_primary_10_2147_PGPM_S460878
crossref_primary_10_1080_14740338_2024_2410436
crossref_primary_10_1111_jon_13255
crossref_primary_10_1124_dmd_123_001466
crossref_primary_10_1016_j_ejcped_2023_100017
crossref_primary_10_1186_s12885_020_6643_8
crossref_primary_10_3390_cancers13215346
crossref_primary_10_1007_s40262_023_01336_1
crossref_primary_10_1177_08258597211030382
crossref_primary_10_1002_mog2_46
crossref_primary_10_3390_jcm12175662
crossref_primary_10_3389_fimmu_2020_626687
crossref_primary_10_1016_j_intimp_2023_110046
crossref_primary_10_3390_bioengineering12010007
crossref_primary_10_1007_s00280_021_04302_5
crossref_primary_10_1182_blood_2019003690
crossref_primary_10_1111_cup_14199
crossref_primary_10_1097_MPH_0000000000002114
crossref_primary_10_1007_s00580_025_03666_x
crossref_primary_10_1007_s11912_023_01449_7
crossref_primary_10_3390_ph17050609
crossref_primary_10_1007_s11916_025_01390_3
crossref_primary_10_1080_10428194_2024_2340051
crossref_primary_10_1007_s00520_024_08894_5
crossref_primary_10_1016_j_ejca_2021_09_014
crossref_primary_10_1016_j_ejmech_2021_113802
crossref_primary_10_1021_acschemneuro_4c00342
crossref_primary_10_1080_17425255_2021_1855141
crossref_primary_10_3390_ijms22084112
crossref_primary_10_1007_s00520_025_09365_1
crossref_primary_10_1002_jbt_70516
crossref_primary_10_1007_s11899_020_00585_2
crossref_primary_10_1007_s12288_025_02047_2
crossref_primary_10_1016_j_ijcard_2022_07_049
crossref_primary_10_2147_ORR_S339064
crossref_primary_10_3390_biom11050633
crossref_primary_10_7759_cureus_74213
crossref_primary_10_11603_ijmmr_2413_6077_2020_1_11503
crossref_primary_10_7759_cureus_18591
crossref_primary_10_1007_s11940_022_00716_5
crossref_primary_10_1016_j_bcp_2024_116070
crossref_primary_10_1146_annurev_pathol_030320_100822
crossref_primary_10_1111_coa_13778
crossref_primary_10_1007_s11060_025_05098_7
crossref_primary_10_3389_fcvm_2023_1243531
crossref_primary_10_1016_j_clml_2025_05_018
crossref_primary_10_1177_03000605231193823
crossref_primary_10_1016_j_jpba_2023_115578
crossref_primary_10_3390_cancers15071963
crossref_primary_10_3390_md20030188
crossref_primary_10_1007_s40487_021_00168_y
crossref_primary_10_1155_2020_2679046
crossref_primary_10_1186_s12906_024_04441_1
crossref_primary_10_1007_s00204_022_03418_8
crossref_primary_10_3390_life14111500
crossref_primary_10_1080_1120009X_2023_2300217
crossref_primary_10_1093_jpp_rgae057
crossref_primary_10_1016_j_expneurol_2020_113519
Cites_doi 10.1007/BF00255486
10.1007/s00277-018-3437-z
10.1002/cncr.10397
10.1093/neuonc/nos203
10.1016/0022-510X(80)90179-3
10.1002/pbc.23039
10.1093/jac/dkr223
10.1007/BF02072486
10.2337/dc06-1499
10.1002/mus.24647
10.1002/cpt.506
10.2217/pgs-2016-0001
10.3109/10428194.2012.697560
10.1097/NCC.0b013e318299ad23
10.1016/0002-9394(76)90725-X
10.1002/1097-0142(19830201)51:3<423::AID-CNCR2820510311>3.0.CO;2-3
10.1016/j.ejca.2008.04.018
10.1016/j.ijporl.2006.09.001
10.1200/jco.2007.12.4784
10.1097/01.mph.0000165130.21539.a3
10.1007/BF01050259
10.3233/JPN-2009-0333
10.1097/mph.0000000000000910
10.12659/MSM.893142
10.1111/jns.12114
10.1016/j.ccr.2008.07.002
10.1016/S1040-8428(98)00023-7
10.1016/j.ejpn.2017.12.019
10.1002/pbc.21435
10.1097/00043426-200304000-00010
10.1080/0284186X.2017.1415462
10.1016/s1091853103003239
10.1159/000204462
10.1128/AAC.46.1.160-165.2002
10.1182/blood-2006-06-027714
10.1177/0883073814535495
10.1002/pbc.26525
10.1016/0163-7258(91)90004-6
10.1007/BF00313556
10.2169/internalmedicine.47.0701
10.1080/14737140.2017.1374856
10.1016/j.ejca.2005.02.012
10.1097/MPH.0b013e3181e01584
10.1046/j.1365-2141.2003.04430.x
10.2165/00003088-200038020-00002
10.1038/86882
10.1097/MPH.0000000000000825
10.1016/s1470-2045(10)70206-0
10.1007/PL00007853
10.1097/CAD.0b013e32833db89d
10.1038/s41397-017-0003-3
10.1007/s12098-010-0096-z
10.1007/s00520-016-3441-6
10.3109/08880018.2011.624163
10.1002/(SICI)1097-0142(19980101)82:1<200::AID-CNCR87>3.0.CO;2-5
10.1023/A:1008389607293
10.1136/bmj.1.6113.610
10.1200/jco.1996.14.3.935
10.1002/1097-0142(19890815)64:4<801::AID-CNCR2820640406>3.0.CO;2-E
10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
10.2217/pgs.14.68
10.1002/pbc.26204
10.1111/j.1651-2227.2001.tb03257.x
10.1097/FPC.0000000000000191
10.1001/archneur.1992.00530340043016
10.1002/neu.480110304
10.1007/s11136-010-9670-0
10.7326/0003-4819-151-4-200908180-00135
10.1007/s00432-003-0524-9
10.1002/cncr.20071
10.1002/pbc.25384
10.1212/01.wnl.0000154642.45474.28
10.1007/bf02759902
10.1097/MPH.0b013e3181e9038d
10.1007/s00520-012-1591-8
10.3816/CLML.2010.n.025
10.1007/s00520-010-1043-2
10.1136/bmj.1.6071.1251
10.1046/j.1365-2257.1998.00103.x
10.1124/dmd.106.009902
10.1002/1097-0142(19940515)73:10<2515::AID-CNCR2820731011>3.0.CO;2-G
10.1007/s00520-013-1981-6
10.1177/1078155214553143
10.1001/archinte.1973.03650110061013
10.1182/blood-2006-10-054528
10.1097/COC.0b013e3181e1d0c0
10.1001/jama.2015.0894
10.1007/BF01697985
10.1002/pbc.26471
10.1111/j.1529-8027.2009.00230.x
10.1002/cpt.1179
10.1177/0883073813491829
10.1016/j.leukres.2010.01.026
10.1002/1097-0142(19810515)47:10<2404::AID-CNCR2820471014>3.0.CO;2-2
10.1016/1040-8428(93)90006-P
10.1007/s00520-017-3780-y
10.1016/j.jaapos.2003.07.010
10.14740/jocmr1856w
10.4103/1817-1745.154358
10.1002/pbc.26854
10.1097/MPH.0000000000001220
10.1111/j.1529-8027.2007.00141.x
10.1002/pbc.22845
10.1007/BF00179439
10.3928/01913913-20150629-01
10.1016/j.spen.2012.02.011
10.1007/s00277-015-2514-9
10.1097/nrl.0000000000000105
10.17724/jicna.2017.75
ContentType Journal Article
Copyright The Author(s) 2019
Cancer Chemotherapy and Pharmacology is a copyright of Springer, (2019). All Rights Reserved. © 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2019
– notice: Cancer Chemotherapy and Pharmacology is a copyright of Springer, (2019). All Rights Reserved. © 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7TO
7X7
7XB
88E
8AO
8C1
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.1007/s00280-019-03884-5
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central
ProQuest One Community College
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Public Health
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Oncogenes and Growth Factors Abstracts
MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1432-0843
EndPage 485
ExternalDocumentID PMC6682573
31214762
10_1007_s00280_019_03884_5
Genre Systematic Review
Journal Article
GroupedDBID ---
-53
-56
-5G
-BR
-EM
-~C
.86
.VR
06C
06D
0R~
0VY
1N0
203
29B
29~
2J2
2JN
2JY
2KG
2KM
2LR
2~H
30V
36B
4.4
406
408
409
40D
40E
5GY
5RE
5VS
67Z
6NX
6PF
78A
7X7
88E
8AO
8C1
8FI
8FJ
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANZL
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAWTL
AAYIU
AAYQN
AAYZH
ABAKF
ABBBX
ABBXA
ABDZT
ABECU
ABFTV
ABHLI
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABKTR
ABLJU
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABSXP
ABTEG
ABTKH
ABTMW
ABUWG
ABUWZ
ABWNU
ABXPI
ACAOD
ACDTI
ACGFS
ACHSB
ACHVE
ACHXU
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACZOJ
ADBBV
ADHHG
ADHIR
ADIMF
ADINQ
ADJJI
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFJLC
AFKRA
AFLOW
AFQWF
AFRAH
AFWTZ
AFZKB
AGAYW
AGDGC
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
B-.
BA0
BDATZ
BENPR
BGNMA
BPHCQ
BSONS
BVXVI
C6C
CCPQU
CS3
CSCUP
DDRTE
DL5
DNIVK
DPUIP
DU5
EBD
EBLON
EBS
EIOEI
EJD
EMB
EMOBN
ESBYG
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
GQ8
GXS
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IHE
IJ-
IKXTQ
IMOTQ
ITM
IWAJR
IXC
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
KDC
KOV
KPH
LAS
LLZTM
M1P
M4Y
MA-
MK0
N9A
NB0
NPVJJ
NQJWS
NU0
O93
O9G
O9I
O9J
OAM
P19
P2P
P9S
PF0
PQQKQ
PROAC
PSQYO
PT4
PT5
Q2X
QOK
QOR
QOS
R89
R9I
RHV
RNS
ROL
RPX
RRX
RSV
S16
S27
S37
S3B
SAP
SBL
SDH
SDM
SHX
SISQX
SJYHP
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
TSG
TSK
TSV
TT1
TUC
U2A
U9L
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WJK
WK8
YLTOR
Z45
Z7U
Z82
Z83
Z87
Z8O
Z8V
Z8W
Z91
ZMTXR
ZOVNA
~EX
~KM
-Y2
.GJ
1SB
2.D
28-
2P1
2VQ
3O-
53G
5QI
AANXM
AAPKM
AARHV
AAYTO
AAYXX
ABBRH
ABDBE
ABFSG
ABQSL
ABRTQ
ABULA
ACBXY
ACSTC
ACUDM
ADHKG
AEBTG
AEFIE
AEKMD
AEZWR
AFDYV
AFDZB
AFEXP
AFFHD
AFFNX
AFHIU
AFOHR
AGGDS
AGQPQ
AHPBZ
AHWEU
AIXLP
AJBLW
ATHPR
AYFIA
BBWZM
CAG
CITATION
COF
EN4
GRRUI
H13
KOW
N2Q
NDZJH
O9-
PHGZM
PHGZT
PJZUB
PPXIY
R4E
RNI
RZK
S1Z
S26
S28
SCLPG
SDE
T16
Y6R
ZGI
CGR
CUY
CVF
ECM
EIF
NPM
RIG
3V.
7TO
7XB
8FK
H94
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c540t-ce4d37385d312b1f1430ad516b614406530ebda8a04af9ed20d9ea4c96eb05d23
IEDL.DBID 8C1
ISICitedReferencesCount 91
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000478903100002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0344-5704
1432-0843
IngestDate Tue Nov 04 02:00:00 EST 2025
Fri Sep 05 06:11:58 EDT 2025
Sat Nov 08 14:35:16 EST 2025
Mon Jul 21 06:05:01 EDT 2025
Tue Nov 18 22:34:20 EST 2025
Sat Nov 29 04:45:34 EST 2025
Fri Feb 21 02:33:15 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Biomarkers
Vincristine-induced neuropathy
Neurotoxicity
Hematologic malignancies
Vincristine
Language English
License Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c540t-ce4d37385d312b1f1430ad516b614406530ebda8a04af9ed20d9ea4c96eb05d23
Notes ObjectType-Article-1
ObjectType-Evidence Based Healthcare-3
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
OpenAccessLink https://link.springer.com/10.1007/s00280-019-03884-5
PMID 31214762
PQID 2242644309
PQPubID 48447
PageCount 15
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_6682573
proquest_miscellaneous_2243491423
proquest_journals_2242644309
pubmed_primary_31214762
crossref_citationtrail_10_1007_s00280_019_03884_5
crossref_primary_10_1007_s00280_019_03884_5
springer_journals_10_1007_s00280_019_03884_5
PublicationCentury 2000
PublicationDate 2019-09-01
PublicationDateYYYYMMDD 2019-09-01
PublicationDate_xml – month: 09
  year: 2019
  text: 2019-09-01
  day: 01
PublicationDecade 2010
PublicationPlace Berlin/Heidelberg
PublicationPlace_xml – name: Berlin/Heidelberg
– name: Germany
– name: Heidelberg
PublicationTitle Cancer chemotherapy and pharmacology
PublicationTitleAbbrev Cancer Chemother Pharmacol
PublicationTitleAlternate Cancer Chemother Pharmacol
PublicationYear 2019
Publisher Springer Berlin Heidelberg
Springer Nature B.V
Publisher_xml – name: Springer Berlin Heidelberg
– name: Springer Nature B.V
References Broyl, Corthals, Jongen, van der Holt, Kuiper, de Knegt, van Duin, el Jarari, Bertsch, Lokhorst, Durie, Goldschmidt, Sonneveld (CR58) 2010; 11
Wang, Lew, Casciano, Clement, Johnson (CR110) 2002; 46
Takahashi, Kameoka, Yamanaka, Ubukawa, Saito, Fujishima, Fujishima, Saito, Hirokawa, Scott, Sawada (CR70) 2008; 47
Bohme, Ganser, Hoelzer (CR72) 1995; 71
Akbayram, Akgun, Dogan, Sayin, Caksen, Oner (CR82) 2010; 77
Brunello, Kapoor, Extermann (CR47) 2011; 34
Anghelescu, Faughnan, Jeha, Relling, Hinds, Sandlund, Cheng, Pei, Hankins, Pauley, Pui (CR44) 2011; 57
Renbarger, McCammack, Rouse, Hall (CR57) 2008; 50
Miller, Hoogstraten, Staquet, Winkler (CR97) 1981; 47
Kanbayashi, Hosokawa, Okamoto, Konishi, Otsuji, Yoshikawa, Takagi, Taniwaki (CR49) 2010; 21
Re, Schwenk, Hegener, Bamborschke, Diehl, Tesch (CR52) 2000; 11
Riga, Psarommatis, Korres, Varvutsi, Giotakis, Apostolopoulos, Ferekidis (CR21) 2007; 71
Morth, Valachis, Sabaa, Molin, Flogegard, Enblad (CR7) 2018; 97
Lash, Williams, Marsh, Crithchley, Hodgkins, MacKie (CR17) 2004; 8
Chauvenet, Shashi, Selsky, Morgan, Kurtzberg, Bell (CR51) 2003; 25
Toker, Yenice, Ogut (CR18) 2004; 8
Scheithauer, Ludwig, Maida (CR24) 1985; 3
Gilchrist (CR100) 2012; 19
Whittaker, Griffith (CR23) 1977; 1
Le-Rademacher, Kanwar, Seisler, Pachman, Qin, Abyzov, Ruddy, Banck, Lavoie Smith, Dorsey, Aaronson, Sloan, Loprinzi, Beutler (CR43) 2017; 25
Moghrabi, Levy, Asselin, Barr, Clavell, Hurwitz, Samson, Schorin, Dalton, Lipshultz, Neuberg, Gelber, Cohen, Sallan, Silverman (CR29) 2007; 109
Kellie, Barbaric, Koopmans, Earl, Carr, de Graaf (CR28) 2002; 94
CR41
Ceppi, Langlois-Pelletier, Gagne, Rousseau, Ciolino, De Lorenzo, Kevin, Cijov, Sallan, Silverman, Neuberg, Kutok, Sinnett, Laverdiere, Krajinovic (CR60) 2014; 15
Guiheneuc, Ginet, Groleau, Rojouan (CR37) 1980; 45
Smitherman, Faircloth, Deal, Troy, Gold (CR69) 2017
Ryan, Emami (CR80) 1983; 51
Watkins, Griffin (CR88) 1978; 1
Kavcic, Koritnik, Krzan, Velikonja, Prelog, Stefanovic, Debeljak, Jazbec (CR9) 2017; 39
Wright, Amstutz, Drogemoller, Shih, Rassekh, Hayden, Carleton, Ross (CR68) 2018
van Schie, Bruggemann, Hoogerbrugge, te Loo (CR76) 2011; 66
Cavaletti, Frigeni, Lanzani, Piatti, Rota, Briani, Zara, Plasmati, Pastorelli, Caraceni, Pace, Manicone, Lissoni, Colombo, Bianchi, Zanna (CR99) 2007; 12
Latiff, Kamal, Jahendran, Alias, Goh, Syed Zakaria, Jamal (CR22) 2010; 32
Ibañez-Juliá, Berzero, Reyes-Botero, Maisonobe, Lenglet, Slim, Louis, Balaguer, Sanson, Le Guern, Latour, Ricard, Stojkovic, Psimaras (CR50) 2018; 57
Vainionpaa (CR95) 1993; 152
Mahajan, Ikeda, Myers, Baldini (CR20) 1981; 47
Gilchrist, Marais, Tanner (CR34) 2014; 22
Bakogeorgos, Georgoulias (CR101) 2017; 17
Hussain, Wozniak, Edelstein (CR102) 1993; 14
Verstappen, Koeppen, Heimans, Huijgens, Scheulen, Strumberg, Kiburg, Postma (CR91) 2005; 64
Utsu, Takaishi, Inagaki, Arai, Yuasa, Masuda, Matsuura, Aotsuka, Wakita (CR6) 2016; 95
Gutierrez-Camino, Martin-Guerrero, Lopez-Lopez, Echebarria-Barona, Zabalza, Ruiz, Guerra-Merino, Garcia-Orad (CR63) 2016; 26
Adhikari, Dongol, Hewett, Shah (CR12) 2014; 34
Cheung, Hicks, Leitch (CR77) 2010; 10
Diouf, Crews, Lew, Pei, Cheng, Bao, Zheng, Yang, Fan, Wheeler, Wing, Delaney, Komatsu, Paugh, McCorkle, Lu, Winick, Carroll, Loh, Hunger, Devidas, Pui, Dolan, Relling, Evans (CR61) 2015; 313
Lopez-Lopez, Gutierrez-Camino, Astigarraga, Navajas, Echebarria-Barona, Garcia-Miguel, Garcia de Andoin, Lobo, Guerra-Merino, Martin-Guerrero, Garcia-Orad (CR65) 2016; 17
Kishi, Cheng, French, Pei, Das, Cook, Hijiya, Rizzari, Rosner, Frudakis, Pui, Evans, Relling (CR56) 2007; 109
Postma, Aaronson, Heimans, Muller, Hildebrand, Delattre, Hoang-Xuan, Lanteri-Minet, Grant, Huddart, Moynihan, Maher, Lucey (CR42) 2005; 41
Hirvonen, Salmi, Heinonen, Antila, Valimaki (CR36) 1989; 64
Tomiwa, Mikawa, Hazama, Yazawa, Hosoya, Ohya, Nishimura (CR26) 1983; 229
Gidding, Kellie, Kamps, de Graaf (CR2) 1999; 29
Tay, Lee, Ong, Goh, Ariffin, Fong (CR89) 2017
Gilchrist, Tanner, Ness (CR96) 2017; 64
Trotti, Colevas, Setser, Basch (CR98) 2007; 25
Wolf, Barton, Kottschade, Grothey, Loprinzi (CR103) 2008; 44
Chan, Worth, Ochs (CR8) 1980; 11
Desai, Van den Berg, Bridges, Shanks (CR46) 1982; 8
van Kooten, van Diemen, Groenhout, Huijgens, Ossenkoppele, Nauta, Heimans (CR81) 1992; 49
Teusink, Ragucci, Shatat, Kalpatthi (CR73) 2012; 29
Postma, Benard, Huijgens, Ossenkoppele, Heimans (CR90) 1993; 15
How, Blattner, Fowler, Wang-Gillam, Schindler (CR25) 2016; 21
Weintraub, Adde, Venzon, Shad, Horak, Neely, Seibel, Gootenberg, Arndt, Nieder, Magrath (CR79) 1996; 14
Bay, Yilmaz, Yilmaz, Oner (CR15) 2006; 73
Jain, Gulati, Toteja, Bakhshi, Seth, Pandey (CR45) 2015; 30
Gillies, Hung, Fitzsimons, Soutar (CR74) 1998; 20
Harila-Saari, Vainionpää, Kovala, Tolonen, Lanning (CR87) 1998; 82
Venkatakrishnan, von Moltke, Greenblatt (CR109) 2000; 38
Ngamphaiboon, Sweeney, Wetzler, Wang (CR19) 2010; 34
Toopchizadeh, Barzegar, Rezamand, Feiz (CR38) 2009; 7
Gulliford, Charlton, Latinovic (CR106) 2006; 29
Gascoigne, Taylor (CR4) 2008; 14
Skiles, Chiang, Li, Martin, Smith, Olbara, Jones, Vik, Mostert, Abbink, Kaspers, Li, Njuguna, Sajdyk, Renbarger (CR67) 2018
Dennison, Kulanthaivel, Barbuch, Renbarger, Ehlhardt, Hall (CR107) 2006; 34
Weiser, Cabanillas, Konopleva, Thomas, Pierce, Escalante, Kantarjian, O’Brien (CR48) 2004; 100
Egbelakin, Ferguson, MacGill, Lehmann, Topletz, Quinney, Li, McCammack, Hall, Renbarger (CR59) 2011; 56
Sands, Ladas, Kelly, Weiner, Lin, Ndao, Dave, Vahdat, Bender (CR84) 2017; 25
Koeppen, Verstappen, Korte, Scheulen, Strumberg, Postma, Heimans, Huijgens, Kiburg, Renzing-Kohler, Diener (CR85) 2004; 130
El Hayek, Trad, Jamil (CR11) 2005; 27
Stock, Diouf, Crews, Pei, Cheng, Laumann, Mandrekar, Luger, Advani, Stone, Larson, Evans (CR62) 2017; 101
Gutierrez-Camino, Umerez, Martin-Guerrero, Garcia de Andoin, Santos, Sastre, Echebarria-Barona, Astigarraga, Navajas, Garcia-Orad (CR5) 2017
Quasthoff, Hartung (CR104) 2002; 249
Mokhtar, Shaaban, Elbarbary, Fayed (CR10) 2010; 32
Kamaluddin, McNally, Breatnach, O’Marcaigh, Webb, O’Dell, Scanlon, Butler, O’Meara (CR75) 2001; 90
Grisold, Cavaletti, Windebank (CR105) 2012; 14
Gilchrist, Tanner (CR33) 2013; 21
Courtemanche, Magot, Ollivier, Rialland, Leclair-Visonneau, Fayet, Camdessanche, Pereon (CR39) 2015; 52
Palkar, Nair, Desai, Potdar, Shinde (CR14) 2015; 52
Aplenc, Glatfelter, Han, Rappaport, La, Cnaan, Blackwood, Lange, Rebbeck (CR55) 2003; 122
Sanderson, Kuwabara, Cogan (CR13) 1976; 81
Nikanjam, Sun, Albers, Mangalindin, Song, Vempaty, Sam, Capparelli (CR71) 2018; 40
Lavoie Smith, Li, Chiang, Thomas, Hutchinson, Wells, Ho, Skiles, Chakraborty, Bridges, Renbarger (CR93) 2015; 20
Moher, Liberati, Tetzlaff, Altman (CR31) 2009; 151
Kayilioglu, Kocak, Kan Karaer, Percin, Sal, Tekkesin, Isik, Oner, Belen, Yilmaz Keskin, Okur, Albayrak, Kaya, Pinarli, Yenicesu, Karadeniz, Oguz, Gursel (CR66) 2017; 39
Kuehl, Zhang, Lin, Lamba, Assem, Schuetz, Watkins, Daly, Wrighton, Hall, Maurel, Relling, Brimer, Yasuda, Venkataramanan, Strom, Thummel, Boguski, Schuetz (CR108) 2001; 27
Yang, Yu, Chen, Hu, Wang (CR1) 2015; 21
Ramchandren, Leonard, Mody, Donohue, Moyer, Hutchinson, Gurney (CR40) 2009; 14
Correia (CR3) 1991; 52
Lavoie Smith, Li, Hutchinson, Ho, Burnette, Wells, Bridges, Renbarger (CR35) 2013; 36
Robertson, Bhoopalam, Zelkowitz (CR27) 1973; 132
Okada, Hanafusa, Sakurada, Teraoka, Kujime, Abe, Shinohara, Kawazoe, Minakuchi (CR54) 2014; 6
Lieber, Blankenburg, Apel, Hirschfeld, Hernaiz Driever, Reindl (CR32) 2018; 22
Kautio, Haanpää, Kautiainen, Kalso, Saarto (CR30) 2011; 19
Haim, Epelbaum, Ben-Shahar, Yarnitsky, Simri, Robinson (CR92) 1994; 73
Kim, Park, Roh, Jeong, Kim, Park, Cho, So, Oh, Kim (CR94) 2010; 19
Sims (CR64) 2016; 22
Jain, Gulati, Seth, Bakhshi, Toteja, Pandey (CR86) 2014; 29
Bhushan, Bhargava, Kasundra, Shubhakaran, Sood (CR53) 2015; 10
Ezzat, Cheung, Hicks, Boro, Montaner, Lima, Harris, Leitch (CR78) 2012; 53
Soysal, Ferhanoglu, Bilir, Akman (CR16) 1993; 90
Bradfield, Sandler, Geller, Tamura, Krischer (CR83) 2015; 62
EM Lavoie Smith (3884_CR35) 2013; 36
A Bay (3884_CR15) 2006; 73
PA Sanderson (3884_CR13) 1976; 81
B Bhushan (3884_CR53) 2015; 10
P Kuehl (3884_CR108) 2001; 27
A Broyl (3884_CR58) 2010; 11
L Gilchrist (3884_CR100) 2012; 19
E Lopez-Lopez (3884_CR65) 2016; 17
CG Tay (3884_CR89) 2017
ZR Desai (3884_CR46) 1982; 8
JJ Correia (3884_CR3) 1991; 52
A Egbelakin (3884_CR59) 2011; 56
M Kavcic (3884_CR9) 2017; 39
HE Hirvonen (3884_CR36) 1989; 64
GM Mokhtar (3884_CR10) 2010; 32
LS Gilchrist (3884_CR33) 2013; 21
F Ceppi (3884_CR60) 2014; 15
A Brunello (3884_CR47) 2011; 34
M El Hayek (3884_CR11) 2005; 27
B Diouf (3884_CR61) 2015; 313
A Bohme (3884_CR72) 1995; 71
L Vainionpaa (3884_CR95) 1993; 152
GL Robertson (3884_CR27) 1973; 132
P Guiheneuc (3884_CR37) 1980; 45
E-j Wang (3884_CR110) 2002; 46
S Ramchandren (3884_CR40) 2009; 14
J How (3884_CR25) 2016; 21
TJ Postma (3884_CR90) 1993; 15
N Takahashi (3884_CR70) 2008; 47
M Riga (3884_CR21) 2007; 71
LS Gilchrist (3884_CR96) 2017; 64
ZA Latiff (3884_CR22) 2010; 32
W Grisold (3884_CR105) 2012; 14
SM Watkins (3884_CR88) 1978; 1
TJ Postma (3884_CR42) 2005; 41
A Gutierrez-Camino (3884_CR63) 2016; 26
EM Lavoie Smith (3884_CR93) 2015; 20
MJ Ibañez-Juliá (3884_CR50) 2018; 57
D Re (3884_CR52) 2000; 11
JB Dennison (3884_CR107) 2006; 34
LS Gilchrist (3884_CR34) 2014; 22
S Adhikari (3884_CR12) 2014; 34
GEB Wright (3884_CR68) 2018
AL Kautio (3884_CR30) 2011; 19
T Soysal (3884_CR16) 1993; 90
RM van Schie (3884_CR76) 2011; 66
P Jain (3884_CR86) 2014; 29
V Toopchizadeh (3884_CR38) 2009; 7
JR Ryan (3884_CR80) 1983; 51
S Akbayram (3884_CR82) 2010; 77
S Koeppen (3884_CR85) 2004; 130
A Gutierrez-Camino (3884_CR5) 2017
J Gillies (3884_CR74) 1998; 20
HM Ezzat (3884_CR78) 2012; 53
D Moher (3884_CR31) 2009; 151
BJ Kim (3884_CR94) 2010; 19
JL Skiles (3884_CR67) 2018
B van Kooten (3884_CR81) 1992; 49
H Kayilioglu (3884_CR66) 2017; 39
JA Whittaker (3884_CR23) 1977; 1
C Morth (3884_CR7) 2018; 97
SJ Kellie (3884_CR28) 2002; 94
MA Weiser (3884_CR48) 2004; 100
AR Chauvenet (3884_CR51) 2003; 25
CC Verstappen (3884_CR91) 2005; 64
M Weintraub (3884_CR79) 1996; 14
L Yang (3884_CR1) 2015; 21
AB Miller (3884_CR97) 1981; 47
SC Lash (3884_CR17) 2004; 8
P Jain (3884_CR45) 2015; 30
AC Teusink (3884_CR73) 2012; 29
M Kamaluddin (3884_CR75) 2001; 90
DL Anghelescu (3884_CR44) 2011; 57
Y Utsu (3884_CR6) 2016; 95
S Quasthoff (3884_CR104) 2002; 249
K Tomiwa (3884_CR26) 1983; 229
A Moghrabi (3884_CR29) 2007; 109
N Okada (3884_CR54) 2014; 6
N Ngamphaiboon (3884_CR19) 2010; 34
J Le-Rademacher (3884_CR43) 2017; 25
RP Sims (3884_CR64) 2016; 22
S Lieber (3884_CR32) 2018; 22
H Courtemanche (3884_CR39) 2015; 52
Y Kanbayashi (3884_CR49) 2010; 21
G Cavaletti (3884_CR99) 2007; 12
SL Mahajan (3884_CR20) 1981; 47
M Bakogeorgos (3884_CR101) 2017; 17
S Sands (3884_CR84) 2017; 25
W Scheithauer (3884_CR24) 1985; 3
AB Smitherman (3884_CR69) 2017
K Venkatakrishnan (3884_CR109) 2000; 38
S Wolf (3884_CR103) 2008; 44
W Stock (3884_CR62) 2017; 101
N Haim (3884_CR92) 1994; 73
3884_CR41
JL Renbarger (3884_CR57) 2008; 50
M Hussain (3884_CR102) 1993; 14
AH Palkar (3884_CR14) 2015; 52
R Aplenc (3884_CR55) 2003; 122
A Trotti (3884_CR98) 2007; 25
CE Gidding (3884_CR2) 1999; 29
M Nikanjam (3884_CR71) 2018; 40
SM Bradfield (3884_CR83) 2015; 62
E Toker (3884_CR18) 2004; 8
S Kishi (3884_CR56) 2007; 109
KE Gascoigne (3884_CR4) 2008; 14
MC Gulliford (3884_CR106) 2006; 29
AH Harila-Saari (3884_CR87) 1998; 82
MC Cheung (3884_CR77) 2010; 10
SY Chan (3884_CR8) 1980; 11
References_xml – volume: 8
  start-page: 211
  issue: 2
  year: 1982
  end-page: 214
  ident: CR46
  article-title: Can severe vincristine neurotoxicity be prevented?
  publication-title: Cancer Chemother Pharmacol
  doi: 10.1007/BF00255486
– volume: 97
  start-page: 2129
  issue: 11
  year: 2018
  end-page: 2135
  ident: CR7
  article-title: Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?
  publication-title: Ann Hematol
  doi: 10.1007/s00277-018-3437-z
– volume: 94
  start-page: 1815
  issue: 6
  year: 2002
  end-page: 1820
  ident: CR28
  article-title: Cerebrospinal fluid concentrations of vincristine after bolus intravenous dosing: a surrogate marker of brain penetration
  publication-title: Cancer
  doi: 10.1002/cncr.10397
– volume: 14
  start-page: 45
  issue: Suppl. 4
  year: 2012
  end-page: 54
  ident: CR105
  article-title: Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention
  publication-title: Neuro-oncology
  doi: 10.1093/neuonc/nos203
– volume: 45
  start-page: 355
  issue: 2–3
  year: 1980
  end-page: 366
  ident: CR37
  article-title: Early phase of vincristine neuropathy in man. Electrophysiological evidence for a dying-back phenomenon, with transitory enhancement of spinal transmission of the monosynaptic reflex
  publication-title: J Neurol Sci
  doi: 10.1016/0022-510X(80)90179-3
– volume: 57
  start-page: 1147
  issue: 7
  year: 2011
  end-page: 1153
  ident: CR44
  article-title: Neuropathic pain during treatment for childhood acute lymphoblastic leukemia
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.23039
– volume: 66
  start-page: 1853
  issue: 8
  year: 2011
  end-page: 1856
  ident: CR76
  article-title: Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dkr223
– volume: 152
  start-page: 115
  issue: 2
  year: 1993
  end-page: 119
  ident: CR95
  article-title: Clinical neurological findings of children with acute lymphoblastic leukaemia at diagnosis and during treatment
  publication-title: Eur J Pediatr
  doi: 10.1007/BF02072486
– volume: 29
  start-page: 2728
  issue: 12
  year: 2006
  end-page: 2729
  ident: CR106
  article-title: Risk of diabetes associated with prescribed glucocorticoids in a large population
  publication-title: Diabetes Care
  doi: 10.2337/dc06-1499
– volume: 52
  start-page: 981
  issue: 6
  year: 2015
  end-page: 985
  ident: CR39
  article-title: Vincristine-induced neuropathy: atypical electrophysiological patterns in children
  publication-title: Muscle Nerve
  doi: 10.1002/mus.24647
– volume: 101
  start-page: 391
  issue: 3
  year: 2017
  end-page: 395
  ident: CR62
  article-title: An inherited genetic variant in CEP72 promoter predisposes to vincristine-induced peripheral neuropathy in adults with acute lymphoblastic leukemia
  publication-title: Clin Pharmacol Ther
  doi: 10.1002/cpt.506
– volume: 17
  start-page: 731
  issue: 7
  year: 2016
  end-page: 741
  ident: CR65
  article-title: Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia
  publication-title: Pharmacogenomics
  doi: 10.2217/pgs-2016-0001
– volume: 53
  start-page: 2390
  issue: 12
  year: 2012
  end-page: 2396
  ident: CR78
  article-title: Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma
  publication-title: Leukemia Lymphoma
  doi: 10.3109/10428194.2012.697560
– volume: 36
  start-page: E49
  issue: 5
  year: 2013
  end-page: E60
  ident: CR35
  article-title: Measuring vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia
  publication-title: Cancer Nurs
  doi: 10.1097/NCC.0b013e318299ad23
– volume: 81
  start-page: 146
  issue: 2
  year: 1976
  end-page: 150
  ident: CR13
  article-title: Optic neuropathy presumably caused by vincristine therapy
  publication-title: Am J Ophthalmol
  doi: 10.1016/0002-9394(76)90725-X
– volume: 51
  start-page: 423
  issue: 3
  year: 1983
  end-page: 425
  ident: CR80
  article-title: Vincristine neurotoxicity with residual equinocavus deformity in children with acute leukemia
  publication-title: Cancer
  doi: 10.1002/1097-0142(19830201)51:3<423::AID-CNCR2820510311>3.0.CO;2-3
– volume: 44
  start-page: 1507
  issue: 11
  year: 2008
  end-page: 1515
  ident: CR103
  article-title: Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2008.04.018
– volume: 71
  start-page: 63
  issue: 1
  year: 2007
  end-page: 69
  ident: CR21
  article-title: Neurotoxicity of vincristine on the medial olivocochlear bundle
  publication-title: Int J Pediatr Otorhinolaryngol
  doi: 10.1016/j.ijporl.2006.09.001
– volume: 25
  start-page: 5121
  issue: 32
  year: 2007
  end-page: 5127
  ident: CR98
  article-title: Patient-reported outcomes and the evolution of adverse event reporting in oncology
  publication-title: J Clin Oncol
  doi: 10.1200/jco.2007.12.4784
– volume: 27
  start-page: 286
  issue: 5
  year: 2005
  end-page: 287
  ident: CR11
  article-title: Vincristine-induced urinary bladder paralysis
  publication-title: J Pediatr Hematol Oncol
  doi: 10.1097/01.mph.0000165130.21539.a3
– volume: 15
  start-page: 23
  issue: 1
  year: 1993
  end-page: 27
  ident: CR90
  article-title: Long-term effects of vincristine on the peripheral nervous system
  publication-title: J Neurooncol
  doi: 10.1007/BF01050259
– volume: 7
  start-page: 351
  issue: 4
  year: 2009
  end-page: 356
  ident: CR38
  article-title: Electrophysiological consequences of vincristine contained chemotherapy in children: a cohort study
  publication-title: J Pediatr Neurol
  doi: 10.3233/JPN-2009-0333
– volume: 39
  start-page: 458
  issue: 6
  year: 2017
  end-page: 462
  ident: CR66
  article-title: Association of CYP3A5 expression and vincristine neurotoxicity in pediatric malignancies in Turkish population
  publication-title: J Pediatr Hematol Oncol
  doi: 10.1097/mph.0000000000000910
– volume: 21
  start-page: 1656
  year: 2015
  end-page: 1661
  ident: CR1
  article-title: Clinical analysis of adverse drug reactions between vincristine and triazoles in children with acute lymphoblastic leukemia
  publication-title: Med Sci Monit
  doi: 10.12659/MSM.893142
– volume: 20
  start-page: 37
  issue: 1
  year: 2015
  end-page: 46
  ident: CR93
  article-title: Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia
  publication-title: J Periph Nerv Syst
  doi: 10.1111/jns.12114
– volume: 14
  start-page: 111
  issue: 2
  year: 2008
  end-page: 122
  ident: CR4
  article-title: Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2008.07.002
– volume: 29
  start-page: 267
  issue: 3
  year: 1999
  end-page: 287
  ident: CR2
  article-title: Vincristine revisited
  publication-title: Crit Rev Oncol Hematol
  doi: 10.1016/S1040-8428(98)00023-7
– volume: 22
  start-page: 457
  issue: 3
  year: 2018
  end-page: 469
  ident: CR32
  article-title: Small-fiber neuropathy and pain sensitization in survivors of pediatric acute lymphoblastic leukemia
  publication-title: Eur J Paediatr Neurol EJPN
  doi: 10.1016/j.ejpn.2017.12.019
– volume: 50
  start-page: 769
  issue: 4
  year: 2008
  end-page: 771
  ident: CR57
  article-title: Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.21435
– volume: 25
  start-page: 316
  issue: 4
  year: 2003
  end-page: 320
  ident: CR51
  article-title: Vincristine-induced neuropathy as the initial presentation of Charcot–Marie–Tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study
  publication-title: J Pediatr Hematol Oncol
  doi: 10.1097/00043426-200304000-00010
– volume: 57
  start-page: 403
  issue: 3
  year: 2018
  end-page: 411
  ident: CR50
  article-title: Antineoplastic agents exacerbating Charcot Marie Tooth disease: red flags to avoid permanent disability
  publication-title: Acta Oncol
  doi: 10.1080/0284186X.2017.1415462
– volume: 8
  start-page: 69
  issue: 1
  year: 2004
  end-page: 71
  ident: CR18
  article-title: Isolated abducens nerve palsy induced by vincristine therapy
  publication-title: J AAPOS
  doi: 10.1016/s1091853103003239
– volume: 90
  start-page: 209
  issue: 4
  year: 1993
  end-page: 210
  ident: CR16
  article-title: Oculomotor nerve palsy associated with vincristine treatment
  publication-title: Acta Haematol
  doi: 10.1159/000204462
– volume: 46
  start-page: 160
  issue: 1
  year: 2002
  end-page: 165
  ident: CR110
  article-title: Interaction of common azole antifungals with P glycoprotein
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.46.1.160-165.2002
– volume: 109
  start-page: 896
  issue: 3
  year: 2007
  end-page: 904
  ident: CR29
  article-title: Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia
  publication-title: Blood
  doi: 10.1182/blood-2006-06-027714
– volume: 30
  start-page: 786
  issue: 6
  year: 2015
  end-page: 788
  ident: CR45
  article-title: Serum alpha tocopherol, vitamin B12, and folate levels in childhood acute lymphoblastic leukemia survivors with and without neuropathy
  publication-title: J Child Neurol
  doi: 10.1177/0883073814535495
– year: 2017
  ident: CR69
  article-title: Vincristine toxicity with co-administration of fluconazole during induction therapy for pediatric acute lymphoblastic leukemia
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.26525
– volume: 52
  start-page: 127
  issue: 2
  year: 1991
  end-page: 147
  ident: CR3
  article-title: Effects of antimitotic agents on tubulin–nucleotide interactions
  publication-title: Pharmacol Ther
  doi: 10.1016/0163-7258(91)90004-6
– volume: 229
  start-page: 267
  issue: 4
  year: 1983
  end-page: 272
  ident: CR26
  article-title: Syndrome of inappropriate secretion of antidiuretic hormone caused by vincristine therapy: a case report of the neuropathology
  publication-title: J Neurol
  doi: 10.1007/BF00313556
– volume: 47
  start-page: 651
  issue: 7
  year: 2008
  end-page: 653
  ident: CR70
  article-title: Itraconazole oral solution enhanced vincristine neurotoxicity in five patients with malignant lymphoma
  publication-title: Intern Med (Tokyo, Japan)
  doi: 10.2169/internalmedicine.47.0701
– volume: 17
  start-page: 1045
  issue: 11
  year: 2017
  end-page: 1060
  ident: CR101
  article-title: Risk-reduction and treatment of chemotherapy-induced peripheral neuropathy
  publication-title: Expert Rev Anticancer Ther
  doi: 10.1080/14737140.2017.1374856
– volume: 41
  start-page: 1135
  issue: 8
  year: 2005
  end-page: 1139
  ident: CR42
  article-title: The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20
  publication-title: Eur J Cancer (Oxford, England: 1990)
  doi: 10.1016/j.ejca.2005.02.012
– volume: 32
  start-page: 407
  issue: 5
  year: 2010
  end-page: 410
  ident: CR22
  article-title: Vincristine-induced vocal cord palsy: case report and review of the literature
  publication-title: J Pediatr Hematol Oncol
  doi: 10.1097/MPH.0b013e3181e01584
– volume: 122
  start-page: 240
  issue: 2
  year: 2003
  end-page: 244
  ident: CR55
  article-title: CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia
  publication-title: Br J Haematol
  doi: 10.1046/j.1365-2141.2003.04430.x
– volume: 38
  start-page: 111
  issue: 2
  year: 2000
  end-page: 180
  ident: CR109
  article-title: Effects of the antifungal agents on oxidative drug metabolism: clinical relevance
  publication-title: Clin Pharmacokinet
  doi: 10.2165/00003088-200038020-00002
– volume: 27
  start-page: 383
  issue: 4
  year: 2001
  end-page: 391
  ident: CR108
  article-title: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
  publication-title: Nat Genet
  doi: 10.1038/86882
– volume: 39
  start-page: 266
  issue: 4
  year: 2017
  end-page: 271
  ident: CR9
  article-title: Electrophysiological studies to detect peripheral neuropathy in children treated with vincristine
  publication-title: J Pediatr Hematol Oncol
  doi: 10.1097/MPH.0000000000000825
– volume: 11
  start-page: 1057
  issue: 11
  year: 2010
  end-page: 1065
  ident: CR58
  article-title: Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial
  publication-title: Lancet Oncol
  doi: 10.1016/s1470-2045(10)70206-0
– volume: 249
  start-page: 9
  issue: 1
  year: 2002
  end-page: 17
  ident: CR104
  article-title: Chemotherapy-induced peripheral neuropathy
  publication-title: J Neurol
  doi: 10.1007/PL00007853
– volume: 21
  start-page: 877
  issue: 9
  year: 2010
  end-page: 881
  ident: CR49
  article-title: Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis
  publication-title: Anticancer Drugs
  doi: 10.1097/CAD.0b013e32833db89d
– year: 2017
  ident: CR5
  article-title: Mir-pharmacogenetics of vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia
  publication-title: Pharmacogenom J
  doi: 10.1038/s41397-017-0003-3
– volume: 77
  start-page: 681
  issue: 6
  year: 2010
  end-page: 683
  ident: CR82
  article-title: Use of pyridoxine and pyridostigmine in children with vincristine-induced neuropathy
  publication-title: Indian J Pediatr
  doi: 10.1007/s12098-010-0096-z
– volume: 25
  start-page: 701
  issue: 3
  year: 2017
  end-page: 708
  ident: CR84
  article-title: Glutamine for the treatment of vincristine-induced neuropathy in children and adolescents with cancer
  publication-title: Support Care Cancer
  doi: 10.1007/s00520-016-3441-6
– volume: 29
  start-page: 62
  issue: 1
  year: 2012
  end-page: 67
  ident: CR73
  article-title: Potentiation of vincristine toxicity with concomitant fluconazole prophylaxis in children with acute lymphoblastic leukemia
  publication-title: Pediatr Hematol Oncol
  doi: 10.3109/08880018.2011.624163
– volume: 82
  start-page: 200
  issue: 1
  year: 1998
  end-page: 207
  ident: CR87
  article-title: Nerve lesions after therapy for childhood acute lymphoblastic leukemia
  publication-title: Cancer
  doi: 10.1002/(SICI)1097-0142(19980101)82:1<200::AID-CNCR87>3.0.CO;2-5
– volume: 11
  start-page: 217
  issue: 2
  year: 2000
  end-page: 220
  ident: CR52
  article-title: Guillain-Barre syndrome in a patient with non-Hodgkin’s lymphoma
  publication-title: Ann Oncol
  doi: 10.1023/A:1008389607293
– volume: 1
  start-page: 610
  issue: 6113
  year: 1978
  end-page: 612
  ident: CR88
  article-title: High incidence of vincristine-induced neuropathy in lymphomas
  publication-title: BMJ
  doi: 10.1136/bmj.1.6113.610
– ident: CR41
– volume: 14
  start-page: 935
  issue: 3
  year: 1996
  end-page: 940
  ident: CR79
  article-title: Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine
  publication-title: J Clin Oncol
  doi: 10.1200/jco.1996.14.3.935
– volume: 64
  start-page: 801
  issue: 4
  year: 1989
  end-page: 805
  ident: CR36
  article-title: Vincristine treatment of acute lymphoblastic leukemia induces transient autonomic cardioneuropathy
  publication-title: Cancer
  doi: 10.1002/1097-0142(19890815)64:4<801::AID-CNCR2820640406>3.0.CO;2-E
– volume: 47
  start-page: 207
  issue: 1
  year: 1981
  end-page: 214
  ident: CR97
  article-title: Reporting results of cancer treatment
  publication-title: Cancer
  doi: 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
– volume: 15
  start-page: 1105
  issue: 8
  year: 2014
  end-page: 1116
  ident: CR60
  article-title: Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia
  publication-title: Pharmacogenomics
  doi: 10.2217/pgs.14.68
– volume: 64
  start-page: 180
  issue: 1
  year: 2017
  end-page: 187
  ident: CR96
  article-title: Short-term recovery of chemotherapy-induced peripheral neuropathy after treatment for pediatric non-CNS cancer
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.26204
– volume: 90
  start-page: 1204
  issue: 10
  year: 2001
  end-page: 1207
  ident: CR75
  article-title: Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies
  publication-title: Acta Paediatr
  doi: 10.1111/j.1651-2227.2001.tb03257.x
– volume: 26
  start-page: 100
  issue: 2
  year: 2016
  end-page: 102
  ident: CR63
  article-title: Lack of association of the CEP72 RS924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population
  publication-title: Pharmacogenet Genom
  doi: 10.1097/FPC.0000000000000191
– volume: 49
  start-page: 1027
  issue: 10
  year: 1992
  end-page: 1031
  ident: CR81
  article-title: A pilot study on the influence of a corticotropin (4–9) analogue on Vinca alkaloid-induced neuropathy
  publication-title: Arch Neurol
  doi: 10.1001/archneur.1992.00530340043016
– volume: 11
  start-page: 251
  issue: 3
  year: 1980
  end-page: 264
  ident: CR8
  article-title: Block of axoplasmic transport in vitro by vinca alkaloids
  publication-title: J Neurobiol
  doi: 10.1002/neu.480110304
– volume: 34
  start-page: 6731
  issue: 11
  year: 2014
  end-page: 6733
  ident: CR12
  article-title: Vincristine-induced blindness: a case report and review of literature
  publication-title: Anticancer Res
– volume: 19
  start-page: 1097
  issue: 8
  year: 2010
  end-page: 1103
  ident: CR94
  article-title: Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma
  publication-title: Q Life Res
  doi: 10.1007/s11136-010-9670-0
– volume: 151
  start-page: 264
  issue: 4
  year: 2009
  end-page: 269
  ident: CR31
  article-title: Preferred reporting items for systematic reviews and meta-analyses: the prisma statement
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-151-4-200908180-00135
– volume: 130
  start-page: 153
  issue: 3
  year: 2004
  end-page: 160
  ident: CR85
  article-title: Lack of neuroprotection by an ACTH (4–9) analogue. A randomized trial in patients treated with vincristine for Hodgkin’s or non-Hodgkin’s lymphoma
  publication-title: J Cancer Res Clin Oncol
  doi: 10.1007/s00432-003-0524-9
– volume: 100
  start-page: 1179
  issue: 6
  year: 2004
  end-page: 1185
  ident: CR48
  article-title: Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen
  publication-title: Cancer
  doi: 10.1002/cncr.20071
– volume: 62
  start-page: 1004
  issue: 6
  year: 2015
  end-page: 1010
  ident: CR83
  article-title: Glutamic acid not beneficial for the prevention of vincristine neurotoxicity in children with cancer
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.25384
– volume: 64
  start-page: 1076
  issue: 6
  year: 2005
  end-page: 1077
  ident: CR91
  article-title: Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening
  publication-title: Neurology
  doi: 10.1212/01.wnl.0000154642.45474.28
– volume: 73
  start-page: 531
  issue: 6
  year: 2006
  end-page: 533
  ident: CR15
  article-title: Vincristine induced cranial polyneuropathy
  publication-title: Indian J Pediatr
  doi: 10.1007/bf02759902
– volume: 32
  start-page: 594
  issue: 8
  year: 2010
  end-page: 600
  ident: CR10
  article-title: A trial to assess the efficacy of glutamic acid in prevention of vincristine-induced neurotoxicity in pediatric malignancies: a pilot study
  publication-title: J Pediatr Hematol Oncol
  doi: 10.1097/MPH.0b013e3181e9038d
– volume: 21
  start-page: 847
  issue: 3
  year: 2013
  end-page: 856
  ident: CR33
  article-title: The pediatric-modified total neuropathy score: a reliable and valid measure of chemotherapy-induced peripheral neuropathy in children with non-CNS cancers
  publication-title: Support Care Cancer
  doi: 10.1007/s00520-012-1591-8
– volume: 10
  start-page: E22
  issue: 2
  year: 2010
  end-page: E25
  ident: CR77
  article-title: Excessive neurotoxicity with ABVD when combined with protease inhibitor-based antiretroviral therapy in the treatment of AIDS-related Hodgkin lymphoma
  publication-title: Clin Lymphoma Myeloma Leukemia
  doi: 10.3816/CLML.2010.n.025
– volume: 19
  start-page: 1991
  issue: 12
  year: 2011
  end-page: 1996
  ident: CR30
  article-title: Burden of chemotherapy-induced neuropathy-a cross-sectional study
  publication-title: Support Care Cancer
  doi: 10.1007/s00520-010-1043-2
– volume: 1
  start-page: 1251
  issue: 6071
  year: 1977
  end-page: 1252
  ident: CR23
  article-title: Recurrent laryngeal nerve paralysis in patients receiving vincristine and vinblastine
  publication-title: BMJ
  doi: 10.1136/bmj.1.6071.1251
– volume: 20
  start-page: 123
  issue: 2
  year: 1998
  end-page: 124
  ident: CR74
  article-title: Severe vincristine toxicity in combination with itraconazole
  publication-title: Clin Lab Haematol
  doi: 10.1046/j.1365-2257.1998.00103.x
– volume: 34
  start-page: 1317
  issue: 8
  year: 2006
  end-page: 1327
  ident: CR107
  article-title: Selective metabolism of vincristine in vitro by CYP3A5
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.106.009902
– volume: 73
  start-page: 2515
  issue: 10
  year: 1994
  end-page: 2519
  ident: CR92
  article-title: Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas
  publication-title: Cancer
  doi: 10.1002/1097-0142(19940515)73:10<2515::AID-CNCR2820731011>3.0.CO;2-G
– volume: 22
  start-page: 359
  issue: 2
  year: 2014
  end-page: 366
  ident: CR34
  article-title: Comparison of two chemotherapy-induced peripheral neuropathy measurement approaches in children
  publication-title: Support Care Cancer
  doi: 10.1007/s00520-013-1981-6
– volume: 22
  start-page: 76
  issue: 1
  year: 2016
  end-page: 81
  ident: CR64
  article-title: The effect of race on the CYP3A-mediated metabolism of vincristine in pediatric patients with acute lymphoblastic leukemia
  publication-title: J Oncol Pharm Pract
  doi: 10.1177/1078155214553143
– volume: 132
  start-page: 717
  issue: 5
  year: 1973
  end-page: 720
  ident: CR27
  article-title: Vincristine neurotoxicity and abnormal secretion of antidiuretic hormone
  publication-title: Arch Intern Med
  doi: 10.1001/archinte.1973.03650110061013
– volume: 109
  start-page: 4151
  issue: 10
  year: 2007
  end-page: 4157
  ident: CR56
  article-title: Ancestry and pharmacogenetics of antileukemic drug toxicity
  publication-title: Blood
  doi: 10.1182/blood-2006-10-054528
– volume: 34
  start-page: 292
  issue: 3
  year: 2011
  end-page: 296
  ident: CR47
  article-title: Hyperglycemia during chemotherapy for hematologic and solid tumors is correlated with increased toxicity
  publication-title: Am J Clin Oncol
  doi: 10.1097/COC.0b013e3181e1d0c0
– volume: 313
  start-page: 815
  issue: 8
  year: 2015
  end-page: 823
  ident: CR61
  article-title: Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia
  publication-title: JAMA
  doi: 10.1001/jama.2015.0894
– volume: 71
  start-page: 311
  issue: 6
  year: 1995
  end-page: 312
  ident: CR72
  article-title: Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL
  publication-title: Ann Hematol
  doi: 10.1007/BF01697985
– year: 2017
  ident: CR89
  article-title: Vincristine-induced peripheral neuropathy in survivors of childhood acute lymphoblastic leukaemia
  publication-title: Pediatric Blood Cancer
  doi: 10.1002/pbc.26471
– volume: 14
  start-page: 184
  issue: 3
  year: 2009
  end-page: 189
  ident: CR40
  article-title: Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia
  publication-title: J Periph Nerv Syst JPNS
  doi: 10.1111/j.1529-8027.2009.00230.x
– year: 2018
  ident: CR68
  article-title: Pharmacogenomics of vincristine-induced peripheral neuropathy implicates pharmacokinetic and inherited neuropathy genes
  publication-title: Clin Pharmacol Ther
  doi: 10.1002/cpt.1179
– volume: 29
  start-page: 932
  issue: 7
  year: 2014
  end-page: 937
  ident: CR86
  article-title: Vincristine-induced neuropathy in childhood all (acute lymphoblastic leukemia) survivors: prevalence and electrophysiological characteristics
  publication-title: J Child Neurol
  doi: 10.1177/0883073813491829
– volume: 34
  start-page: e194
  issue: 8
  year: 2010
  end-page: e196
  ident: CR19
  article-title: Pyridoxine treatment of vincristine-induced cranial polyneuropathy in an adult patient with acute lymphocytic leukemia: case report and review of the literature
  publication-title: Leuk Res
  doi: 10.1016/j.leukres.2010.01.026
– volume: 47
  start-page: 2404
  issue: 10
  year: 1981
  end-page: 2406
  ident: CR20
  article-title: Acute acoustic nerve palsy associated with vincristine therapy
  publication-title: Cancer
  doi: 10.1002/1097-0142(19810515)47:10<2404::AID-CNCR2820471014>3.0.CO;2-2
– volume: 14
  start-page: 61
  issue: 1
  year: 1993
  end-page: 75
  ident: CR102
  article-title: Neurotoxicity of antineoplastic agents
  publication-title: Crit Rev Oncol Hematol
  doi: 10.1016/1040-8428(93)90006-P
– volume: 25
  start-page: 3537
  issue: 11
  year: 2017
  end-page: 3544
  ident: CR43
  article-title: Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials
  publication-title: Supportive Care Cancer
  doi: 10.1007/s00520-017-3780-y
– volume: 8
  start-page: 67
  issue: 1
  year: 2004
  end-page: 68
  ident: CR17
  article-title: Acute sixth-nerve palsy after vincristine therapy
  publication-title: J AAPOS
  doi: 10.1016/j.jaapos.2003.07.010
– volume: 6
  start-page: 252
  issue: 4
  year: 2014
  end-page: 260
  ident: CR54
  article-title: Risk factors for early-onset peripheral neuropathy caused by vincristine in patients with a first administration of R-CHOP or R-CHOP-like chemotherapy
  publication-title: J Clin Med Res
  doi: 10.14740/jocmr1856w
– volume: 10
  start-page: 64
  issue: 1
  year: 2015
  end-page: 66
  ident: CR53
  article-title: Guillain-Barre syndrome in acute lymphoblastic leukemia: causal or coincidental
  publication-title: J Pediatr Neurosci
  doi: 10.4103/1817-1745.154358
– year: 2018
  ident: CR67
  article-title: CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.26854
– volume: 40
  start-page: e273
  issue: 5
  year: 2018
  end-page: e277
  ident: CR71
  article-title: Vincristine-associated neuropathy with antifungal usage: a kaiser northern California experience
  publication-title: J Pediatr Hematol Oncol
  doi: 10.1097/MPH.0000000000001220
– volume: 12
  start-page: 210
  issue: 3
  year: 2007
  end-page: 215
  ident: CR99
  article-title: The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale
  publication-title: J Periph Nerv Syst JPNS
  doi: 10.1111/j.1529-8027.2007.00141.x
– volume: 56
  start-page: 361
  issue: 3
  year: 2011
  end-page: 367
  ident: CR59
  article-title: Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.22845
– volume: 3
  start-page: 315
  issue: 3
  year: 1985
  end-page: 318
  ident: CR24
  article-title: Acute encephalopathy associated with continuous vincristine sulfate combination therapy: case report
  publication-title: Invest New Drugs
  doi: 10.1007/BF00179439
– volume: 52
  start-page: 34
  year: 2015
  end-page: 37
  ident: CR14
  article-title: Vincristine-induced neuropathy presenting as ptosis and ophthalmoplegia in a 2-year-old boy
  publication-title: J Pediatr Ophthalmol Strabismus
  doi: 10.3928/01913913-20150629-01
– volume: 19
  start-page: 9
  issue: 1
  year: 2012
  end-page: 17
  ident: CR100
  article-title: Chemotherapy-induced peripheral neuropathy in pediatric cancer patients
  publication-title: Semin Pediatr Neurol
  doi: 10.1016/j.spen.2012.02.011
– volume: 95
  start-page: 41
  issue: 1
  year: 2016
  end-page: 47
  ident: CR6
  article-title: Influence of dose reduction of vincristine in R-CHOP on outcomes of diffuse large B cell lymphoma
  publication-title: Ann Hematol
  doi: 10.1007/s00277-015-2514-9
– volume: 21
  start-page: 112
  issue: 6
  year: 2016
  end-page: 117
  ident: CR25
  article-title: Chemotherapy-associated posterior reversible encephalopathy syndrome: a case report and review of the literature
  publication-title: Neurologist
  doi: 10.1097/nrl.0000000000000105
– volume: 32
  start-page: 407
  issue: 5
  year: 2010
  ident: 3884_CR22
  publication-title: J Pediatr Hematol Oncol
  doi: 10.1097/MPH.0b013e3181e01584
– volume: 34
  start-page: 6731
  issue: 11
  year: 2014
  ident: 3884_CR12
  publication-title: Anticancer Res
– volume: 71
  start-page: 311
  issue: 6
  year: 1995
  ident: 3884_CR72
  publication-title: Ann Hematol
  doi: 10.1007/BF01697985
– volume: 52
  start-page: 34
  year: 2015
  ident: 3884_CR14
  publication-title: J Pediatr Ophthalmol Strabismus
  doi: 10.3928/01913913-20150629-01
– volume: 229
  start-page: 267
  issue: 4
  year: 1983
  ident: 3884_CR26
  publication-title: J Neurol
  doi: 10.1007/BF00313556
– volume: 94
  start-page: 1815
  issue: 6
  year: 2002
  ident: 3884_CR28
  publication-title: Cancer
  doi: 10.1002/cncr.10397
– volume: 11
  start-page: 251
  issue: 3
  year: 1980
  ident: 3884_CR8
  publication-title: J Neurobiol
  doi: 10.1002/neu.480110304
– volume: 109
  start-page: 4151
  issue: 10
  year: 2007
  ident: 3884_CR56
  publication-title: Blood
  doi: 10.1182/blood-2006-10-054528
– volume: 34
  start-page: 292
  issue: 3
  year: 2011
  ident: 3884_CR47
  publication-title: Am J Clin Oncol
  doi: 10.1097/COC.0b013e3181e1d0c0
– volume: 14
  start-page: 184
  issue: 3
  year: 2009
  ident: 3884_CR40
  publication-title: J Periph Nerv Syst JPNS
  doi: 10.1111/j.1529-8027.2009.00230.x
– volume: 12
  start-page: 210
  issue: 3
  year: 2007
  ident: 3884_CR99
  publication-title: J Periph Nerv Syst JPNS
  doi: 10.1111/j.1529-8027.2007.00141.x
– volume: 56
  start-page: 361
  issue: 3
  year: 2011
  ident: 3884_CR59
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.22845
– volume: 249
  start-page: 9
  issue: 1
  year: 2002
  ident: 3884_CR104
  publication-title: J Neurol
  doi: 10.1007/PL00007853
– volume: 25
  start-page: 701
  issue: 3
  year: 2017
  ident: 3884_CR84
  publication-title: Support Care Cancer
  doi: 10.1007/s00520-016-3441-6
– volume: 8
  start-page: 69
  issue: 1
  year: 2004
  ident: 3884_CR18
  publication-title: J AAPOS
  doi: 10.1016/s1091853103003239
– volume: 62
  start-page: 1004
  issue: 6
  year: 2015
  ident: 3884_CR83
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.25384
– volume: 90
  start-page: 1204
  issue: 10
  year: 2001
  ident: 3884_CR75
  publication-title: Acta Paediatr
  doi: 10.1111/j.1651-2227.2001.tb03257.x
– volume: 29
  start-page: 267
  issue: 3
  year: 1999
  ident: 3884_CR2
  publication-title: Crit Rev Oncol Hematol
  doi: 10.1016/S1040-8428(98)00023-7
– volume: 11
  start-page: 1057
  issue: 11
  year: 2010
  ident: 3884_CR58
  publication-title: Lancet Oncol
  doi: 10.1016/s1470-2045(10)70206-0
– volume: 32
  start-page: 594
  issue: 8
  year: 2010
  ident: 3884_CR10
  publication-title: J Pediatr Hematol Oncol
  doi: 10.1097/MPH.0b013e3181e9038d
– year: 2017
  ident: 3884_CR69
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.26525
– volume: 14
  start-page: 61
  issue: 1
  year: 1993
  ident: 3884_CR102
  publication-title: Crit Rev Oncol Hematol
  doi: 10.1016/1040-8428(93)90006-P
– volume: 100
  start-page: 1179
  issue: 6
  year: 2004
  ident: 3884_CR48
  publication-title: Cancer
  doi: 10.1002/cncr.20071
– volume: 17
  start-page: 1045
  issue: 11
  year: 2017
  ident: 3884_CR101
  publication-title: Expert Rev Anticancer Ther
  doi: 10.1080/14737140.2017.1374856
– volume: 29
  start-page: 932
  issue: 7
  year: 2014
  ident: 3884_CR86
  publication-title: J Child Neurol
  doi: 10.1177/0883073813491829
– volume: 19
  start-page: 1991
  issue: 12
  year: 2011
  ident: 3884_CR30
  publication-title: Support Care Cancer
  doi: 10.1007/s00520-010-1043-2
– volume: 64
  start-page: 1076
  issue: 6
  year: 2005
  ident: 3884_CR91
  publication-title: Neurology
  doi: 10.1212/01.wnl.0000154642.45474.28
– volume: 52
  start-page: 127
  issue: 2
  year: 1991
  ident: 3884_CR3
  publication-title: Pharmacol Ther
  doi: 10.1016/0163-7258(91)90004-6
– volume: 44
  start-page: 1507
  issue: 11
  year: 2008
  ident: 3884_CR103
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2008.04.018
– volume: 73
  start-page: 531
  issue: 6
  year: 2006
  ident: 3884_CR15
  publication-title: Indian J Pediatr
  doi: 10.1007/bf02759902
– volume: 6
  start-page: 252
  issue: 4
  year: 2014
  ident: 3884_CR54
  publication-title: J Clin Med Res
  doi: 10.14740/jocmr1856w
– volume: 21
  start-page: 112
  issue: 6
  year: 2016
  ident: 3884_CR25
  publication-title: Neurologist
  doi: 10.1097/nrl.0000000000000105
– volume: 8
  start-page: 211
  issue: 2
  year: 1982
  ident: 3884_CR46
  publication-title: Cancer Chemother Pharmacol
  doi: 10.1007/BF00255486
– volume: 17
  start-page: 731
  issue: 7
  year: 2016
  ident: 3884_CR65
  publication-title: Pharmacogenomics
  doi: 10.2217/pgs-2016-0001
– volume: 66
  start-page: 1853
  issue: 8
  year: 2011
  ident: 3884_CR76
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dkr223
– volume: 73
  start-page: 2515
  issue: 10
  year: 1994
  ident: 3884_CR92
  publication-title: Cancer
  doi: 10.1002/1097-0142(19940515)73:10<2515::AID-CNCR2820731011>3.0.CO;2-G
– volume: 77
  start-page: 681
  issue: 6
  year: 2010
  ident: 3884_CR82
  publication-title: Indian J Pediatr
  doi: 10.1007/s12098-010-0096-z
– volume: 15
  start-page: 23
  issue: 1
  year: 1993
  ident: 3884_CR90
  publication-title: J Neurooncol
  doi: 10.1007/BF01050259
– volume: 22
  start-page: 457
  issue: 3
  year: 2018
  ident: 3884_CR32
  publication-title: Eur J Paediatr Neurol EJPN
  doi: 10.1016/j.ejpn.2017.12.019
– volume: 34
  start-page: e194
  issue: 8
  year: 2010
  ident: 3884_CR19
  publication-title: Leuk Res
  doi: 10.1016/j.leukres.2010.01.026
– volume: 26
  start-page: 100
  issue: 2
  year: 2016
  ident: 3884_CR63
  publication-title: Pharmacogenet Genom
  doi: 10.1097/FPC.0000000000000191
– volume: 14
  start-page: 45
  issue: Suppl. 4
  year: 2012
  ident: 3884_CR105
  publication-title: Neuro-oncology
  doi: 10.1093/neuonc/nos203
– volume: 95
  start-page: 41
  issue: 1
  year: 2016
  ident: 3884_CR6
  publication-title: Ann Hematol
  doi: 10.1007/s00277-015-2514-9
– volume: 3
  start-page: 315
  issue: 3
  year: 1985
  ident: 3884_CR24
  publication-title: Invest New Drugs
  doi: 10.1007/BF00179439
– volume: 36
  start-page: E49
  issue: 5
  year: 2013
  ident: 3884_CR35
  publication-title: Cancer Nurs
  doi: 10.1097/NCC.0b013e318299ad23
– volume: 10
  start-page: E22
  issue: 2
  year: 2010
  ident: 3884_CR77
  publication-title: Clin Lymphoma Myeloma Leukemia
  doi: 10.3816/CLML.2010.n.025
– ident: 3884_CR41
  doi: 10.17724/jicna.2017.75
– volume: 25
  start-page: 5121
  issue: 32
  year: 2007
  ident: 3884_CR98
  publication-title: J Clin Oncol
  doi: 10.1200/jco.2007.12.4784
– volume: 101
  start-page: 391
  issue: 3
  year: 2017
  ident: 3884_CR62
  publication-title: Clin Pharmacol Ther
  doi: 10.1002/cpt.506
– volume: 132
  start-page: 717
  issue: 5
  year: 1973
  ident: 3884_CR27
  publication-title: Arch Intern Med
  doi: 10.1001/archinte.1973.03650110061013
– volume: 21
  start-page: 847
  issue: 3
  year: 2013
  ident: 3884_CR33
  publication-title: Support Care Cancer
  doi: 10.1007/s00520-012-1591-8
– volume: 57
  start-page: 403
  issue: 3
  year: 2018
  ident: 3884_CR50
  publication-title: Acta Oncol
  doi: 10.1080/0284186X.2017.1415462
– volume: 49
  start-page: 1027
  issue: 10
  year: 1992
  ident: 3884_CR81
  publication-title: Arch Neurol
  doi: 10.1001/archneur.1992.00530340043016
– year: 2017
  ident: 3884_CR5
  publication-title: Pharmacogenom J
  doi: 10.1038/s41397-017-0003-3
– volume: 47
  start-page: 2404
  issue: 10
  year: 1981
  ident: 3884_CR20
  publication-title: Cancer
  doi: 10.1002/1097-0142(19810515)47:10<2404::AID-CNCR2820471014>3.0.CO;2-2
– volume: 313
  start-page: 815
  issue: 8
  year: 2015
  ident: 3884_CR61
  publication-title: JAMA
  doi: 10.1001/jama.2015.0894
– volume: 25
  start-page: 316
  issue: 4
  year: 2003
  ident: 3884_CR51
  publication-title: J Pediatr Hematol Oncol
  doi: 10.1097/00043426-200304000-00010
– volume: 29
  start-page: 2728
  issue: 12
  year: 2006
  ident: 3884_CR106
  publication-title: Diabetes Care
  doi: 10.2337/dc06-1499
– volume: 19
  start-page: 9
  issue: 1
  year: 2012
  ident: 3884_CR100
  publication-title: Semin Pediatr Neurol
  doi: 10.1016/j.spen.2012.02.011
– volume: 20
  start-page: 123
  issue: 2
  year: 1998
  ident: 3884_CR74
  publication-title: Clin Lab Haematol
  doi: 10.1046/j.1365-2257.1998.00103.x
– volume: 46
  start-page: 160
  issue: 1
  year: 2002
  ident: 3884_CR110
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.46.1.160-165.2002
– volume: 14
  start-page: 935
  issue: 3
  year: 1996
  ident: 3884_CR79
  publication-title: J Clin Oncol
  doi: 10.1200/jco.1996.14.3.935
– volume: 90
  start-page: 209
  issue: 4
  year: 1993
  ident: 3884_CR16
  publication-title: Acta Haematol
  doi: 10.1159/000204462
– volume: 7
  start-page: 351
  issue: 4
  year: 2009
  ident: 3884_CR38
  publication-title: J Pediatr Neurol
  doi: 10.3233/JPN-2009-0333
– volume: 22
  start-page: 359
  issue: 2
  year: 2014
  ident: 3884_CR34
  publication-title: Support Care Cancer
  doi: 10.1007/s00520-013-1981-6
– volume: 29
  start-page: 62
  issue: 1
  year: 2012
  ident: 3884_CR73
  publication-title: Pediatr Hematol Oncol
  doi: 10.3109/08880018.2011.624163
– volume: 82
  start-page: 200
  issue: 1
  year: 1998
  ident: 3884_CR87
  publication-title: Cancer
  doi: 10.1002/(SICI)1097-0142(19980101)82:1<200::AID-CNCR87>3.0.CO;2-5
– volume: 11
  start-page: 217
  issue: 2
  year: 2000
  ident: 3884_CR52
  publication-title: Ann Oncol
  doi: 10.1023/A:1008389607293
– volume: 151
  start-page: 264
  issue: 4
  year: 2009
  ident: 3884_CR31
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-151-4-200908180-00135
– volume: 22
  start-page: 76
  issue: 1
  year: 2016
  ident: 3884_CR64
  publication-title: J Oncol Pharm Pract
  doi: 10.1177/1078155214553143
– volume: 41
  start-page: 1135
  issue: 8
  year: 2005
  ident: 3884_CR42
  publication-title: Eur J Cancer (Oxford, England: 1990)
  doi: 10.1016/j.ejca.2005.02.012
– volume: 57
  start-page: 1147
  issue: 7
  year: 2011
  ident: 3884_CR44
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.23039
– volume: 52
  start-page: 981
  issue: 6
  year: 2015
  ident: 3884_CR39
  publication-title: Muscle Nerve
  doi: 10.1002/mus.24647
– volume: 64
  start-page: 180
  issue: 1
  year: 2017
  ident: 3884_CR96
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.26204
– volume: 81
  start-page: 146
  issue: 2
  year: 1976
  ident: 3884_CR13
  publication-title: Am J Ophthalmol
  doi: 10.1016/0002-9394(76)90725-X
– volume: 15
  start-page: 1105
  issue: 8
  year: 2014
  ident: 3884_CR60
  publication-title: Pharmacogenomics
  doi: 10.2217/pgs.14.68
– year: 2018
  ident: 3884_CR67
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.26854
– volume: 21
  start-page: 877
  issue: 9
  year: 2010
  ident: 3884_CR49
  publication-title: Anticancer Drugs
  doi: 10.1097/CAD.0b013e32833db89d
– volume: 1
  start-page: 1251
  issue: 6071
  year: 1977
  ident: 3884_CR23
  publication-title: BMJ
  doi: 10.1136/bmj.1.6071.1251
– volume: 39
  start-page: 266
  issue: 4
  year: 2017
  ident: 3884_CR9
  publication-title: J Pediatr Hematol Oncol
  doi: 10.1097/MPH.0000000000000825
– volume: 25
  start-page: 3537
  issue: 11
  year: 2017
  ident: 3884_CR43
  publication-title: Supportive Care Cancer
  doi: 10.1007/s00520-017-3780-y
– volume: 50
  start-page: 769
  issue: 4
  year: 2008
  ident: 3884_CR57
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.21435
– volume: 14
  start-page: 111
  issue: 2
  year: 2008
  ident: 3884_CR4
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2008.07.002
– volume: 51
  start-page: 423
  issue: 3
  year: 1983
  ident: 3884_CR80
  publication-title: Cancer
  doi: 10.1002/1097-0142(19830201)51:3<423::AID-CNCR2820510311>3.0.CO;2-3
– volume: 71
  start-page: 63
  issue: 1
  year: 2007
  ident: 3884_CR21
  publication-title: Int J Pediatr Otorhinolaryngol
  doi: 10.1016/j.ijporl.2006.09.001
– volume: 130
  start-page: 153
  issue: 3
  year: 2004
  ident: 3884_CR85
  publication-title: J Cancer Res Clin Oncol
  doi: 10.1007/s00432-003-0524-9
– volume: 21
  start-page: 1656
  year: 2015
  ident: 3884_CR1
  publication-title: Med Sci Monit
  doi: 10.12659/MSM.893142
– volume: 8
  start-page: 67
  issue: 1
  year: 2004
  ident: 3884_CR17
  publication-title: J AAPOS
  doi: 10.1016/j.jaapos.2003.07.010
– volume: 30
  start-page: 786
  issue: 6
  year: 2015
  ident: 3884_CR45
  publication-title: J Child Neurol
  doi: 10.1177/0883073814535495
– volume: 34
  start-page: 1317
  issue: 8
  year: 2006
  ident: 3884_CR107
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.106.009902
– volume: 53
  start-page: 2390
  issue: 12
  year: 2012
  ident: 3884_CR78
  publication-title: Leukemia Lymphoma
  doi: 10.3109/10428194.2012.697560
– volume: 1
  start-page: 610
  issue: 6113
  year: 1978
  ident: 3884_CR88
  publication-title: BMJ
  doi: 10.1136/bmj.1.6113.610
– volume: 97
  start-page: 2129
  issue: 11
  year: 2018
  ident: 3884_CR7
  publication-title: Ann Hematol
  doi: 10.1007/s00277-018-3437-z
– volume: 47
  start-page: 651
  issue: 7
  year: 2008
  ident: 3884_CR70
  publication-title: Intern Med (Tokyo, Japan)
  doi: 10.2169/internalmedicine.47.0701
– volume: 20
  start-page: 37
  issue: 1
  year: 2015
  ident: 3884_CR93
  publication-title: J Periph Nerv Syst
  doi: 10.1111/jns.12114
– volume: 109
  start-page: 896
  issue: 3
  year: 2007
  ident: 3884_CR29
  publication-title: Blood
  doi: 10.1182/blood-2006-06-027714
– year: 2018
  ident: 3884_CR68
  publication-title: Clin Pharmacol Ther
  doi: 10.1002/cpt.1179
– volume: 40
  start-page: e273
  issue: 5
  year: 2018
  ident: 3884_CR71
  publication-title: J Pediatr Hematol Oncol
  doi: 10.1097/MPH.0000000000001220
– year: 2017
  ident: 3884_CR89
  publication-title: Pediatric Blood Cancer
  doi: 10.1002/pbc.26471
– volume: 38
  start-page: 111
  issue: 2
  year: 2000
  ident: 3884_CR109
  publication-title: Clin Pharmacokinet
  doi: 10.2165/00003088-200038020-00002
– volume: 64
  start-page: 801
  issue: 4
  year: 1989
  ident: 3884_CR36
  publication-title: Cancer
  doi: 10.1002/1097-0142(19890815)64:4<801::AID-CNCR2820640406>3.0.CO;2-E
– volume: 47
  start-page: 207
  issue: 1
  year: 1981
  ident: 3884_CR97
  publication-title: Cancer
  doi: 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
– volume: 19
  start-page: 1097
  issue: 8
  year: 2010
  ident: 3884_CR94
  publication-title: Q Life Res
  doi: 10.1007/s11136-010-9670-0
– volume: 27
  start-page: 383
  issue: 4
  year: 2001
  ident: 3884_CR108
  publication-title: Nat Genet
  doi: 10.1038/86882
– volume: 27
  start-page: 286
  issue: 5
  year: 2005
  ident: 3884_CR11
  publication-title: J Pediatr Hematol Oncol
  doi: 10.1097/01.mph.0000165130.21539.a3
– volume: 10
  start-page: 64
  issue: 1
  year: 2015
  ident: 3884_CR53
  publication-title: J Pediatr Neurosci
  doi: 10.4103/1817-1745.154358
– volume: 152
  start-page: 115
  issue: 2
  year: 1993
  ident: 3884_CR95
  publication-title: Eur J Pediatr
  doi: 10.1007/BF02072486
– volume: 122
  start-page: 240
  issue: 2
  year: 2003
  ident: 3884_CR55
  publication-title: Br J Haematol
  doi: 10.1046/j.1365-2141.2003.04430.x
– volume: 45
  start-page: 355
  issue: 2–3
  year: 1980
  ident: 3884_CR37
  publication-title: J Neurol Sci
  doi: 10.1016/0022-510X(80)90179-3
– volume: 39
  start-page: 458
  issue: 6
  year: 2017
  ident: 3884_CR66
  publication-title: J Pediatr Hematol Oncol
  doi: 10.1097/mph.0000000000000910
SSID ssj0004133
Score 2.5612276
SecondaryResourceType review_article
Snippet Purpose Vincristine is widely used as anticancer therapy for a variety of hematological malignancies. The treatment is limited by progressive...
Vincristine is widely used as anticancer therapy for a variety of hematological malignancies. The treatment is limited by progressive vincristine-induced...
PurposeVincristine is widely used as anticancer therapy for a variety of hematological malignancies. The treatment is limited by progressive...
SourceID pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 471
SubjectTerms Antineoplastic Agents, Phytogenic - adverse effects
Autonomic nervous system
Blood cancer
Cancer Research
Central nervous system
Drug-Related Side Effects and Adverse Reactions - etiology
Drug-Related Side Effects and Adverse Reactions - pathology
Fluconazole
Hematologic Neoplasms - drug therapy
Hematologic Neoplasms - pathology
Humans
Itraconazole
Medicine
Medicine & Public Health
Neurotoxicity
Neurotoxicity Syndromes - etiology
Neurotoxicity Syndromes - pathology
Oncology
Peripheral neuropathy
Pharmacodynamics
Pharmacokinetics
Pharmacology/Toxicology
Prognosis
Quality of life
Review
Review Article
Reviews
Vincristine
Vincristine - adverse effects
Voriconazole
SummonAdditionalLinks – databaseName: Springer LINK
  dbid: RSV
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB7xEuJSKAWaFipXQly6lpzEebg3hIo4AFq1FCEuUWI7sBJkEVmQ9t93bOehLQ8Jzp448Xhsf5PxfAOwG4a-jCKpKYL10vy6KanQXNI0L5SWHCGBve1-fpycnqYXF2LYJIXV7W33NiRpd-ou2c1GAdH1FdQwmHAazcMiHnepWY6__5z32ZC-KyAfcpRJGG9SZZ7vY_Y4eoIxn16V_C9eao-hw9X3DWANPjSwk-w7O_kIc7pah-WTJrC-DntDR2E9HZCzPiOrHpA9MuzJraef4HLf5mbWZFySx1El7R5RaYquPRqJIpYf05Q5npJRRSwjrNteyS0i_itXDLj-SXLSc0gTlz-zAX8Pf50dHNGmPgOViPMmVGquDDFSpEI_KPwSoRfLVeTHhfEyDekt04XK05zxvBRaBUwJnXMpYl2wSAXhJixU40p_BiKKlKskUeg8xZyhNBNFrIKCy1iXmnEP_HaaMtmQl5saGjdZR7tstZuhdjOr3Szy4Ef3zJ2j7nhVerud_axZxnUWOMAYMuHB964ZF6CJquSVHj9YmZALH2GpB1vOWLrXoV58jseNB8mMGXUChtx7tqUaXVuS7zhG3z3BPgetMfWf9fIovrxN_CusBNYezZ25bViY3D_oHViSj5NRff_NLqt_oBMdhA
  priority: 102
  providerName: Springer Nature
Title Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review
URI https://link.springer.com/article/10.1007/s00280-019-03884-5
https://www.ncbi.nlm.nih.gov/pubmed/31214762
https://www.proquest.com/docview/2242644309
https://www.proquest.com/docview/2243491423
https://pubmed.ncbi.nlm.nih.gov/PMC6682573
Volume 84
WOSCitedRecordID wos000478903100002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAVX
  databaseName: SpringerLINK Contemporary 1997-Present
  customDbUrl:
  eissn: 1432-0843
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0004133
  issn: 0344-5704
  databaseCode: RSV
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22
  providerName: Springer Nature
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9wwEB4VqKpe2kJfaenKlSouXatO4jzMpaII1ENZrShFq16ixHbalSBLyYK0_57xYxNtEVy4rBTZycaZh2c8M98AfIrjUCaJ1BSN9doc3dRUaC5pXlZKS44mgc12P_2RjUb5ZCLG_sCt9WmVS51oFbWaSXNG_iVye3fMxNeLf9R0jTLRVd9CYw02wohxI5j5fp_igQratUfmnCYZ475oxpbO2ZgiOtKCGjwUHF_dmG5Zm7eTJv-LnNoN6fD5Q5fyAp55U5TsOd7ZhEe62YInRz7YvgU7YwdrvRiSk75Kqx2SHTLuAa8XL-H3nq3XbMmsJtfTRlq90WiK7j4yjiIWM9O0Pl6QaUMsSqxTueQcvYA_rkFwu0tK0uNKE1dT8wp-HR6c7H-nvmcDlWj7zanUXBmwpETFYVSFNZpjrFRJmFbG8zRAuExXqsxLxstaaBUxJXTJpUh1xRIVxa9hvZk1-i0QUeVcZZlChyrlDGczUaUqqrhMda0ZDyBcEqyQHtDc9NU4KzooZkvkAolcWCIXSQCfu3suHJzHvbO3lwQsvGi3RU-9AD52wyiUJtJSNnp2ZefEXIRoqgbwxrFN93f4XUKOW1AA2QpDdRMM4PfqSDP9a4G_0xT9-QyfOVyyXv9ad6_i3f2reA9PIysGJm9uG9bnl1f6AzyW1_NpezmAtWyS2d98YIVrABvfDkbjY7w6_nl6A5vDK5w
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB5VBUEvPMorUMBI0Atr4STOw0gIVUDVqtvVHha06iUktlMiQbY026L9U_xGxnay0VLRWw-c7bycb172zDcAL8PQl1EkNUVnvTRbNyUVmkua5oXSkqNLYLPdvwyT0SidTsV4DX53tTAmrbLTiVZRq5k0e-RvAme7Qyben_ykpmuUOV3tWmg4WBzoxS8M2Zp3-x_x_74Kgt1Pkw97tO0qQCV6J3MqNVeGzidSoR8UfokOA8tV5MeFiY0MVSvThcrTnPG8FFoFTAmdcyliXbBIGaIDVPnXUI8nJoUsmSZ9HabvWteHnNMoYbwt0rGlevYMEwN3QQ3_Co6vGsIL3u3FJM2_TmqtAdy9_b8t3R241braZMfJxl1Y0_Um3Dhskwk2YXvsaLsXAzLpq9CaAdkm457Qe3EPjnZsPWpDZiU5r2pp9WKtaVUrFAxFLCeoae28IFVNLAuuMynkB0Y5x64BcvOW5KTnzSauZug-fL6SJXgA6_Ws1o-AiCLlKkkUBowxZzibiSJWQcFlrEvNuAd-B5BMtoTtpm_I92xJNW1BlSGoMguqLPLg9fKaE0dXcunsrQ4wWau6mqxHiwcvlsOodMxJUl7r2ZmdE3LhoyvuwUMH0-XjcF18jibWg2QFwMsJhtB8daSuvlli8zhO0YLgPQcd1PvX-vdXPL78K57Dzb3J4TAb7o8OnsBGYEXQ5Ahuwfr89Ew_hevyfF41p8-sMBP4etUi8AedboQe
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9QwFH6qCqq4sJQtUMBI0Atj1UmcxUgIVZQRVctoDgWNuKSJ7UAkyJRmWjR_jV_Hs51FQ0VvPXC2sznf2-z3vgfwIgx9GUVSU3TWS7N1U1KhuaRpXigtOboENtv982EymaSzmZiuwe-uFsakVXY60SpqNZdmj3wncLY7ZGKnbNMipnvjtyc_qekgZU5au3YaDiIHevkLw7fmzf4e_uuXQTB-f_TuA207DFCJnsqCSs2VofaJVOgHhV-i88ByFflxYeIkQ9vKdKHyNGc8L4VWAVNC51yKWBcsUob0ANX_tSQME9M2IpklQ02m79rYh5zTKGG8LdixZXv2PBODeEENFwuOrxrFC57uxYTNv05trTEc3_qfl_E23GxdcLLrZOYOrOl6EzY-tkkGm7A9dXTeyxE5GqrTmhHZJtOB6Ht5F77s2jrVhsxLcl7V0urLWtOqVigwiliuUNPyeUmqmlh2XGdqyA-Mfr66xsjNa5KTgU-buFqie_DpSpbgPqzX81o_BCKKlKskURhIxpzhbCaKWAUFl7EuNeMe-B1YMtkSuZt-It-znoLaAixDgGUWYFnkwav-mhNHY3Lp7K0OPFmr0ppsQI4Hz_thVEbmhCmv9fzMzgm58NFF9-CBg2z_OFwXn6Pp9SBZAXM_wRCdr47U1TdLeB7HKVoWvOeog_3wWv_-ikeXf8Uz2EDkZ4f7k4PHcCOw0mhSB7dgfXF6pp_AdXm-qJrTp1auCRxftQT8AZ8zjNI
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Aspects+of+vincristine-induced+neuropathy+in+hematologic+malignancies%3A+a+systematic+review&rft.jtitle=Cancer+chemotherapy+and+pharmacology&rft.au=Madsen%2C+Marie+Lindhard&rft.au=Due%2C+Hanne&rft.au=Ejskj%C3%A6r%2C+Niels&rft.au=Jensen%2C+Paw&rft.date=2019-09-01&rft.pub=Springer+Nature+B.V&rft.issn=0344-5704&rft.eissn=1432-0843&rft.volume=84&rft.issue=3&rft.spage=471&rft.epage=485&rft_id=info:doi/10.1007%2Fs00280-019-03884-5&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0344-5704&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0344-5704&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0344-5704&client=summon